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SUMMARY 
RING1A and RING1B paralogous proteins are part of the heterodimeric RING finger-type E3 
ligases present in type I Polycomb Repressive Complexes (PRC1). They are responsible for the 
monoubiquitylation of histone H2A that correlates with the transcriptional repression of PRC1 
targets. PRC1 are biochemically heterogeneous entities which have RING1A/RING1B as core 
components present in all of their forms. PRC1 complexes are grouped into canonical and 
non-canonical complexes depending on subunits content and therefore functionally distinct. 
The known biochemical heterogeneity and regulatory complexity of PRC1 assemblies arises 
from cell types departed (tumoral established lines) from in vivo cells. We thus asked how 
faithfully the accepted PRC1 complexes represent those extant in non- or less-altered cell 
types. For this purpose, we set up an experimental system to investigate PRC1 within the 
hematopoietic compartment, in primary cells of different lineage and/or different stage of 
maturation. We used a mouse line that expresses a RING1B variant that can be biotinylated 
by a ubiquitously expressed prokaryotic biotin ligase. The biotinylatable RING1B, knocked-in 
at the RING1B locus, is subject to the same controls as the endogenous gene, thus 
representing a situation as close to the physiological state as possible. Selected hematopoietic 
cell types obtained from these mice, and ex-vivo expanded populations of progenitors were 
used to prepare nuclear extracts from which RING1B and associated proteins were isolated 
using streptavidin beads. We found that levels of PRC1 subunits change from one cell type to 
another. Our results show that RING1A and RING1B segregate, for the most part, into 
different complexes. Likewise, the differences in distribution of PRC1 subunits throughout 
density gradients vary with cell types, without a perceivable pattern. During our attempts of 
studying the content of PRC1 subunits in RING1B complexes, we found that PRC1 assemblies 
in hematopoietic cells are more unstable than complexes in the cell lines commonly used. In 
summary, the data point at the presence of complexes of heterogeneous composition related 
to different maturation stages and different of the nowadays accepted, paradigmatic PRC1. 
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RESUMEN 
Las proteina ligasas E3 de la clase I de complejos represivos Polycomb (PRC1) son 
heterodímeros de proteínas que siempre contienen o RING1A o su homólogo RING1B. La 
actividad protein ligasa de PRC1 es responsable de la monoubiquitinación de la histona H2A. 
Los complejos PRC1 son entidades bioquímicamente heterogéneas, agrupándose en dos 
grandes categorías, canónica y no canónica, definidas por capacidades que más allá de la 
modificación de H2A, presentan funciones exclusivas. La mayor parte del conocimiento actual 
sobre complejos PRC1 deriva de estudios con líneas celulares establecidas a partir de tumores 
o tipos celulares singulares, como las células madre embrionarias que, en conjunto, difieren 
de los tipos celulares que se encuentran in vivo. Nosotros nos hemos preguntado si lo que 
conocemos de PRC1 es una fiel representación de células no alteradas como las que pueden 
encontrarse in vivo o con alteraciones mínimas. Para ello diseñamos un sistema experimental 
para estudiar PRC1 en células primarias de diferente linaje y/o diferente estado de 
maduración dentro del compartimento hematopoyético. El sistema se basa en una línea de 
ratones genéticamente manipulados para conseguir la expresión de una forma de RING1B 
que se puede biotinilar endógenamente y, de esta manera, aislarse con facilidad mediante el 
uso de bolas con estreptavidina inmovilizada. Como la variante de RING1B resulta de la 
modificación del gen endógeno, se puede esperar que tanto su regulación como sus niveles 
se asemejen a los del producto del gen salvaje, es decir, las condiciones extremadamente 
próximas a las fisiológicas. Varios tipos celulares hematopoyéticos seleccionados asì como sus 
derivados expandidos ex-vivo se utilizaron para la preparación de extractos en los que 
determinamos niveles de subunidades PRC1 y sus asociaciones en complejos. Hemos 
encontrado que la expresión de subunidades varía con el tipo celular y que sus niveles 
disminuyen, en células primarias con la diferenciación. También vemos que la mayoría de los 
complejos que contienen RING1B son independientes de los que contienen RING1A, lo que 
sugiere diferencias funcionales no anticipadas, dada la redundancia de parálogos 
identificados. Al aislar complejos que contienen RING1B, hemos observado que las distintas 
subunidades PRC1 se asocian entre sí y a RING1B con afinidades mucho menores que las 
mostradas en complejos de células de líneas establecidas. Junto a la diversidad relacionada 
con el estado de maduración, estos estudios apuntan a la presencia de complejos 
parcialmente distintos de los que constituyen el actual paradigma PRC1. 
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INTRODUCTION 
The genetic material, in eukaryotes, is organized as long nucleoprotein complex(es) that 
display complicated form topological conformations. Access to DNA, the template of all 
encoded products that determine a cellular identity is, therefore, one of the key elements in 
gene regulation. At the most elemental level, chromatin is but a string of DNA wrapped 
around an octamer of duplicated dimers of histones H2A-H2B and histones H3-H4. A large 
collection of proteins, forming a variety of complexes endowed with diverse enzymatic 
activities, is devoted to chromatin regulation. The protein complexes they form are known as 
chromatin regulators. They modify chromatin, from local to high-order structures through a 
highly regulated, interconnected network of protein-protein interactions and enzymatic 
activities. As a result, cis-acting control regions, i.e. promoters and enhancers, the sequences 
that DNA binding proteins bind to among the collection of chromatin regulators, the 
Polycomb system stands out historically by their association with developmental processes. 
1. THE POLYCOMB SISTEM OF CHROMATIN REGULATORS 
The so-called Polycomb system was initially defined genetically,  grouping mutations isolated 
in developmental studies with the fly Drosophila melanogaster (Lewis, 1978).After molecular 
cloning of the Polycomb group (PcG) of genes, it was apparent the multiplicity of unrelated 
proteins involved. Functionally, the derepression of Hox genes in Polycomb mutant larvae and 
the alterations seen in adult flies led to the classification of the products of PcG genes as 
transcriptional repressors (Jürgens, 1985). It is, precisely, the phenotype of adult mutant male 
flies, showing additional sex combs in their first and second pair of legs what coined the term 
Polycomb to name the group of genes that when mutated showed similar phenotypes. PcG 
products assemble in protein complexes, as assessed following biochemical purification, in a 
way consistent with the interactions observed during genetic analysis. Importantly, work in 
other system models soon showed evolutionary conservation so that PcG products are found 
in plants, metazoans and even (some of them, at least) in yeast (Alonso et al., 2007; Levine et 
al., 2002). PcG proteins form two major types of complexes termed Polycomb repressive 
complexes (PRC) (Levine et al., 2002). The two types, contain non-overlapping sets of 
proteins. One class of complexes, PRC2, was first associated with an enzymatic activity that di- 
and try-methylates lysine 27 of histone H3 (H3K27me3) (R. Cao & Zhang, 2004; Czermin et al., 
2002). The other class of complexes, PRC1, can also modify histones, but through 
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monoubiquitylation of histone H2A (H2AUb) (de Napoles et al., 2004; Wang et al.,2004).. 
These modifications and the protein domains responsible are the most conserved portions of 
PcG proteins throughout evolution. 
While PRC1 and PRC2 do not normally associate physically, they colocalize, to some extent, on 
chromatin (Ram et al., 2011). Functionally PRC1 and PRC2 show mutual interdependence at 
certain sites (Farcas et al., 2012; Tavares et al., 2012).  As other chromatin regulators, PRC1 
and PRC2 contain, in addition to the mentioned enzymatic activities, subunits that recognize 
and associate to specific modifications of histone tails (Bernstein et al., 2006; Kaustov et al., 
2011; Min et al.,, 2003), subunits that bind non-specifically DNA or RNA and also subunits 
engaged in protein-protein contacts (Aranda, Mas, & Croce, 2015; Farcas et al., 2012; Kaneko 
et al., 2014; Neira et al., 2009; Yap et al., 2010; Yu et al., 2012). Although initially identified as 
transcriptional repressors, recent evidence points at PRC1 associated also to transcriptionally 
active loci (Creppe et al., 2014; Frangini et al., 2013; Kloet et al., 2016; Loubiere et al., 2016; 
Morey et al., 2015). Despite intense work in many laboratories, the mechanisms underlying 
the activity(es) of PRCs are poorly characterized. This includes their recruitment to targets 
and their influence on the transcriptional process. In mammalian cells most work on the 
Polycomb system has been carried out on the model of embryonic stem cells (ESCs), a 
pluripotent cell type of transient existence in the preimplantation embryo that can be 
maintained in vitro, as sustained in time under conditions that hold their tendency to 
differentiation. It is because they make an excellent model to study in vitro differentiation 
that they are so broadly used. 
2. PRC RECRUITING TO GENOMIC SITES 
In flies, PRC is recruited to so-called Polycomb response elements, short sequences enriched 
in DNA binding sites (Zink & Paro 1989; Ringrose & Paro, 2007) however, similar sites are not 
known in mammalian cells. Instead, PcG complexes locate preferentially to singular genomic 
regions, CpG islands (CGIs) of hundred to few kilobases of sequences enriched in the 
dinucleotide CpG, that, in contrast to sites not so enriched in CpG are free of DNA 
methylation (Farcas et al., 2012). About half of the mammalian promoters are contained 
within CGIs probably due to its unique structure that makes them ideal platforms for gene 
regulation (Deaton & Bird, 2011). PcG complexes locate to CGIs because of KDM2B, a DNA 
binding protein with a domain that specifically recognizes unmethylated CpG sequences and 
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that purifies with a subset of PRC1 complexes (Farcas et al., 2012). Regulatory events not fully 
characterized restrict the presence of PRC1 complexes to some of this sites bound by KDM2B. 
Binding of PRC1 at these sites is accompanied by H2AUb, which in turn is recognized by a 
subunit of PRC2, leading to allosteric activation of the methyltransferase activity of PRC2 
subunit EZH2 (Kalb et al., 2014). Subsequent methylation of H3K27, in turn, increases the 
residence time of some PRC1 complexes at these sites through the recognition of PRC2-
modified H3K27me3 (Blackledge et al., 2014; Kalb et al., 2014). In this way a self-reinforcing 
mechanism is at play at, at least, some regions, although there are other sites where PRC1 
and PRC2 do not colocalize (Ku et al., 2008; van den Boom et al., 2016).  In addition to CGIs, 
other DNA sequences are used for transcription-factor mediated recruiting (Suzuki et al., 
2016; Yu et al., 2012) but these have not been established as general ways of recruiting. 
3. PRC TRANSCRIPTIONAL ACTIVITY 
Two main paths have been explored to explain PRC repression. One, on transcription 
initiation, proposes that PRC1, or its histone modification interact with the assembly of the 
pre initiation complex (Lehmann et al., 2012) or the pausing of RNA polymerase II (Stock et 
al., 2007). Derived from work with ESCs, Polycomb involvement in either mechanisms is not 
settled (Jadhav et al., 2016). 
 
The second mechanism for transcriptional repression is based on the ability to compact 
chromatin, normally dependent on protein-protein interactions. The presence of subunits 
with such an ability on some PRC1 complexes leads to functionally relevant alterations of 
chromatin structure  (Boettiger et al., 2016; Isono et al., 2013; Lau et al., 2017). PRC1 
participates also from long-distance contacts between genomic sites, such as those between 
enhancer and promoters. Their involvement may result in transcriptional activity that can be 
modulated (Kondo et al., 2014; Schoenfelder et al., 2015). 
4. NO TRANSCRIPTIONAL FUNCTIONS OF POLYCOMB COMPLEXES 
The PRC1 complexes always were described as chromatin remodelers which regulate gene 
transcription. Last discovers show that these proteins also have other functions which is not 
associated with transcription machinery. RING1A and RING1B were found to be involved in 
DNA replication (Bravo et al., 2015; Piunti et al., 2014). PCGF4, other component of PRC1 
34 
 
complexes is regulating oxidative stress in hematopoietic compartment (Liu et al., 2009; 
Nakamura et al., 2012) but also DNA damage response (DDR) pathway (X. Lin et al., 2015; Liu 
et al., 2009). Also CBX8 was found to be involved in DDR (Oza et al., 2016). The new evidences 
about novel PRC1 functions shows that there are still remaining questions to answer about 
nature of Polycomb proteins. 
5. PRC1 COMPLEXES 
RING1A and RING1B proteins, with the enzymatic activity of E3 ligase, are a core component 
of PRC1 complexes. These proteins were co-purified with all Polycomb proteins, what suggest 
that plays the main role in Polycomb machinery. Their structure, contain several motifs 
allowing other PRC1 subunits interact. On the N-terminus, the RING finger motif is found 
(Saurin et al., 1996) and is used for interaction with PCGF paralogs. The C-terminus hold the 
RAWUL domain (Ring-finger And WD40 associated Ubiquitin-Like (Sanchez-Pulido et al., 
2008), which participate in interactions with the other PRC1 subunits. 
5.1 Ubiquitination mediated by RING1A and RING1B 
The PRC1 E3 ligase module contains RING1A or RING1B which interact through their RING 
finger domain with one of the six Polycomb group RING finger proteins (PCGFs)(Buchwald et 
al., 2006; Li et al., 2006). Ubiquitination of proteins is a multi-step process, in which E3 ligase 
transfer ubiquitin from the E2 element, specific conjugating enzyme, or ubiquitin carrier 
(Metzger et al., 2014). PRC1 E3 ligases work with UBCH5, specific E2 component, which 
interact exclusively with RING1A or RING1B (Buchwald et al., 2006). The PCGF proteins do not 
interact directly with E2 module but stimulate enzymatic activity of RING proteins, which 
deposit ubiquitin on H2AK119. Ubiquitination of H2A was associated with transcriptional 
repression, because mutation in RING1B leads to loss of H2Ak119ub and activation of Hox 
genes (Cao et al., 2005, Wang et al., 2004).  
5.2 PRC1 heterogeneity (Canonical vs non-canonical) 
Each subunit of Polycomb complex characterized in Drosophila has multiple orthologs in the 
mammalian genome (Otte & Kwaks, 2003; Sparmann & van Lohuizen, 2006), which indicate a 
wide range of possible associations. Depending on the structural composition, PRC1 
complexes are grouped into two main types: canonical- and non-canonical-PRC1. Canonical 
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PRC1 refer to the first complex, purified from HeLa cells containing various CBX proteins 
(homologs of Pc), RING1A and RING1B – subunits with activity analogous to dRing, homologs 
of Ph (PHC1,2,3)  and BMI1/PCGF4 - homolog of Psc.  
The complexes composition and interactions between subunits was poorly understood during 
the years. Various groups were working on biochemical identification of PRC1 using the 
affinity tag purification method. In subunit-independent manner the RING1A/B proteins were 
co-purified and new interactions was identified. The composition and interactions between 
Polycomb proteins were characterized by investigations on subunits as PCGF2 (Elderkin et al., 
2007), PCGF4 (Wiederschain et al., 2007), E2F6 (Ogawa et al., 2002), BCOR and PCGF1 
(Gearhart et al., 2006). A mile step in the Polycomb research was the isolation of the RING1B 
complexes and identification of a high number of novel interactions. Additionally, 
identification of new complex containing KDM2B/FBXL10 and BCOR was assessed in the study 
(Sánchez et al., 2007). At the time there was no evidence explaining the complexity of 
interactions. Recent results, published by Hauri and colleagues where they perform complete 
analysis of Polycomb ineractome in human cells shown how miscellaneous Polycomb 
interaction network could be (Hauri et al., 2016). 
  Canonical PRC1 (PRC1.2, PRC1.4) 
Non-canonical PRC1 
(PRC1.3,PRC1.5, PRC1.6) 
core components RING1A, RING1B RING1A, RING1B 
PCGF proteins PCGF2/MEL18 (PRC1.2/1.4) PCGF1/NSPC1 (PRC1.1) 
 
PCGF4/BMI1 (PRC1.2/1.4) PCGF3 (PRC1.3) 
  
PCGF5 (PRC1.5) 
  
PCGF6/MBLR (PRC1.6) 
chromodomain proteins CBX2/M33, CBX4/PC4, CBX6, CBX7, 
CBX8 (PRC1.2/1.4) 
CBX8 (PRC1.1), CBX3/HP1γ (PRC1.6) 
   Polyhomeiotic homologs PHC1, PHC2, PHC3 (PRC1.2/1.4) 
 Sex Comb on Midleg 
homologs SCML2,SCMH1,SFMBT1(PRC1.4) 
 DNA-binding proteins 
 
KDM2B/FBXL10 (PRC1.1) 
  
MGA-MAX, E2F6-TDFP1(PRC1.6) 
Other subunits RYBP RYBP, YAF2 (PRC1.1,3,5,6) 
  
L3MBTL2, WDR5 (PRC1.6) 
  
SKP1, BCOR (PRC1.1) 
    AUTS2,CSNK2A1/CK2a(PRC1.5) 
 
 
Table I. Canonical and non-canonical PRC1 subunits 
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For long time PRC1 complexes did not have clear and simply classification. The recent one, is 
based on the six family members of the PCGF (Gao et al., 2012). Gao and colleagues purified 
each of PCGFs with a set of associated proteins, that are present in each of PRC1 complexes. 
They suggested to name complexes from PRC1.1 to PRC1.6, depending on PCGF homolog. In 
Table I are presented all subunits divide into categories: canonical and non-canonical. 
The CBX paralogs, which associate with RING proteins by their RAWUL domain have in their 
structure chromo (CHRomatin Organization Modifier) domain which could recognized 
H3K27me3 CBX (Yap & Zhou, 2011) Interaction of CBX proteins with other PRC1 components 
is mutually exclusive (Vandamme et al., 2011). Chromodomains of CBX proteins have different 
affinity to recognize H3K27me3 (Bernstein et al., 2006; Kaustov et al., 2011). Studies in 
embryonic stem cells (ESC) shows that CBX7 and CBX8 recruitment is efficient, whereas CBX2, 
CBX4 and CBX6 not (Zhen et al., 2016). CBX proteins form part of canonical PRC1 
(preferentially) however, they are also found in non-canonical complexes (Beguelin et al., 
2016).   
RYBP and their paralog YAF2 (García et al., 1999) are two proteins which also interact with 
RING1A/B by association to their RAWUL domain. Participation of this proteins in PRC1 
complexes is mutually exclusive with CBX proteins (Tavares et al., 2012). RYBP was found to 
bound to DNA (Neira et al., 2009). It was also proposed to recruit PRC1 complexes to 
chromatin, however the mechanism is not well characterized (Tavares et al., 2012).  
5.3 Is function dependent on the composition?  
Since the composition of PRC1 complexes was defined, it was suggested that different 
complexes may have distinct functions (Luis et al., 2012). Study on genomic localization the 
PCGFFs homologues has shown that promoters are bound exclusively or predominantly by 
only one PCGF (Gao et al., 2012). Those results could imply that every complex has a specific 
target and biological function. The comparison of chromatin occupancy by PRC1-RYBP and 
PRC1-CBX7 complexes has demonstrated that this two distinct complexes can colocalize at 
genomic loci but in general occupy specific for each targets (Morey et al.,2013).  Also it is 
known that RING1A has an ability to compensate RING1B deletion in ES cells, however that is 
not happen with CBXs proteins. Each of the CBX proteins has it specific function that cannot 
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be carried by other members of the family (Creppe et al., 2014; Klauke et al., 2013; Morey et 
al., 2013). 
5.4 Changes in composition during differentiation 
In the context of Polycomb, little is known about the role of heterogeneity of PRC1 in 
differentiation. In ESC and hematopoietic system, CBX7 is involved in self-renewal, but during 
lineage commitment is repressed and  replaced by its paralogs (CBX2, CBX4 or CBX8) (Klauke 
et al., 2013; Morey et al., 2012). Interestingly, in those cells, CBX6  is transcriptionally active 
protein not interacting with PRC1 subunits and just 5% of its genomic occupancy is associated 
with Polycomb proteins (Morey et al., 2012). That result suggests that the CBX6 has non-
Polycomb linked role in those cell types. Changes in composition and targets of PCGF2-
containing complexes during cardiac differentiation shown that PRC1 complexes could play a 
different role on each step of the process (Morey et al., 2015). This study proposes that 
specific PRC1 complexes control different cell types, influencing biological processes during 
differentiation of the cells via activation or repression of the gene transcription.  
Proteomic and genomic studies dedicated to a characterization of PRC1 complexes during 
differentiation of ESC to neural cells have revealed that PRC1 complexes are cell type specific 
(Kloet et al., 2016). Using label-free quantitative proteomic approach, the group 
demonstrated dramatic changes in PCGFs and CBX protein during differentiation. PCGF6 is 
exchanged by PCGF4 and CBX7, which is present only in ESC, is replaced by CBX6 in the neural 
cells. Other examples, highlights, those subunits PHC2 and 3 are present only in differentiated 
neural cells. Genomic studies has shown that in both cell types PRC1 complexes binds to 
different targets, confirming the specific function of each complex. 
5.5 Association with non-Polycomb proteins 
Multiple proteomic analysis identified interactors of RING1B which are PRC1 subunits but also 
proteins which did not belong to the Polycomb family. Various group demonstrate that 
RING1B could interact with other chromatin remodelers, members of SWI/SNF family 
complexes (Stanton et al., 2016).. Other interactors which were found to be associated to 
RING1B probably plays role in Polycomb machinery which could be recruitment mechanism or 
specific role of PRC1. This is still remaining question. 
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It is important to note that most of the above body of knowledge on the nature of PRC1 
complexes (and also of their function) derives from work in a limited and selective cell types. 
Despite evolutionary conservation, the Drosophila model cannot shed light on, for example, 
the mammalian system given the large differences in PRC1 subunits (the conserved regions 
are, basically, restricted to functional domains, such as RING fingers, chromodomains or SAM 
domains). Mammalian systems on which PRC1 has been studied include, in addition to ESCs, 
the humoral cell lines such as human kidney embryo 293 cells, HeLa or MEL (murine 
erythroleukemia). The content of these cells in PRC1 subunits (and, in general, of most 
proteins) is much higher than that in in vivo cells. Besides, their unusual nature (ESCs, cells 
can only deploy a subset of regulatory pathways, channeled towards their transformed 
phenotype.  
With this in mind, we set out to investigate the nature of PRC1 as close as possible to an in 
vivo situation. The possibility that the system appeared still more complicated than already 
known, we aimed at a minimization of variables by restricting our analysis, at least initially, to 
a single cell lineage, the hematopoietic compartment. 
6. HEMATOPOIESIS 
6.1 Normal hematopoiesis 
Hematopoiesis is the process in which progenitor cells give rise to all mature blood cells. It is 
highly dynamic because mature cells has limited life-span and must be continuously replaced. 
This process take place in a bone marrow however, mature cells are migrating to secondary 
hematopoietic organs as thymus, spleen and blood for terminal differentiation. The most 
primitive cell type, the hematopoietic stem cell (HSC) has the highest self-renewal potential 
and gives rise to all hematopoietic cell type. In the adult, HSCs locate predominantly in the 
bone marrow, where they reside for the entire life of organism. HSCs exist in minute numbers 
(0.005% Oguro et al 2013), compared to more differentiated cells. As all stem cells, HSCs 
undergo symmetric and asymmetric divisions to generate daughter HSCs (self-renewal) 
(Morrison & Kimble, 2006) or cells that, upon successive divisions, will become a complex set 
of progenitors differentially primed for distinct cell lineages (Cabezas-Wallscheid et al., 2014; 
Hérault et al., 2017; A. Wilson et al., 2008). Following the committed cell fate, progenitors 
become the precursors of fully differentiated mature cells. Lacking any of surface molecules 
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termed lineage markers, some of which univocally identify cell lineages (for example, CD19 on 
lymphoid precursors of B cells, or Ter119, on erythroid cells, progenitors are referred to as 
the pool of lineage negative (Lin-) cells in the bone marrow. Another cell population of 
relevance is one expressing c-kit, the receptor for an important cytokine, the stem cell factor, 
also known as kit-ligand) present in more or less undifferentiated cells, including many Lin- 
cells. Figure I1, shows one of the best accepted paradigms of hematopoietic differentiation, 
noting relationships between progenitors, precursors and mature cells. It contains three 
major lineages: megakaryo-erythroid, myeloid and lymphoid. Maturation within the first two 
is attained within the bone marrow from where platelets, erythrocytes and a variety of 
myeloid cells, such as neutrophil, granulocytes or macrophages leave for the blood stream. 
The lymphoid lineage, on the other hand, i.e. B and T-cells leave the bone marrow to house in 
secondary hematopoietic organs, spleen and thymus, respectively (lymph nodes, too), where 
their fully functional capacities are acquired. In general, lymphoid cells have a much longer 
lifespan than myeloid cells, implying that most hematopoiesis is spent generating short-lived 
myeloid cell types. B-cells arriving to the spleen constitute a major component of splenic cell 
population.  
 
Figure I1. Hematopoietic differentiation. HSC- hematopoietic stem cell, MPP – multipotent progenitor, CLP – 
Common lymphoid progenitor, CMP – common lymphoid progenitor, MEP-megakaryo-erythrocytic progenitor, 
GMP- granulocyte/macrophage progenitor. 
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They are primed for death from where a subset of them are rescued and maintained in a 
quiescent state before engaging full immune activity activated by antigens (Osmond, 1993).  
Likewise, T-cell precursors arriving at the thymus are selected for survival upon successful 
recognition of complexes between self-peptide and proteins of the major histocompatibility 
complex, a prior step to their final maturation (Tough & Sprent, 1996). 
6.2 Aberrant hematopoiesis 
Probably the best studied cell compartment, networks of transcription factors and cis-control 
regions have been identified with roles in hematopoiesis (Calero-Nieto et al., 2014; Gottgens, 
2015; Huang et al., 2013; Paul et al., 2015). This knowledge has provided an understanding, in 
molecular terms, of many of the events associated to aberrant hematopoiesis, the 
malignization of hematopoietic cell types characteristic of the hematopoietic disease. 
Characteristically, the differentiation process is wired, within defined transcriptional 
programs, to the cessation of cell proliferation. In malignant hematopoiesis, alterations of 
normal regulators with roles in transcription, usually fusion proteins resulting from 
chromosomal translocations (Yokoyama, 2016), changes their regulatory properties and 
corrupts the program, often blocking cells in an intermediate differentiation state endowed 
with proliferation capacity(Y. W. Lin & Aplan, 2004). It is the case of myeloid leukemias, in 
which the product of the Trithorax group gene Mll1/KMT2A fuses its 5'-sequences to those 
segments of genes encoding, for example, elements of the transcription elongation 
machinery. Examples are Mll-ENL or Mll-Af9 proteins, which are actively used in the 
generation of mouse models of acute leukemia (AML) (Somervaille & Cleary, 2006) 
7. FUNCTIONS OF PRC1 IN HEMATOPOIESIS 
 
Chromatin regulators play critical functions in differentiation and tissue homeostasis and as 
such, perturbation of the Polycomb system, through both loss-of and gain-of-function 
mutations in genes encoding PcG subunits, leads to hematopoietic alterations. 
In general, the genetic analysis showed, initially, a consistent association with the promotion 
of cell proliferation. More recent evidence points also to functions restricting cell 
proliferation. Sought after alterations of cell fate, however, are reared and not as prevalent as 
those related to deregulated proliferation. Focusing on mutations in genes encoding PRC1 
subunits, the phenotypes could be considered within two large sets of functions: 
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7.1 Role in self-renewal 
Loss of PCGF4 leads to decreasing of HSC number in mice (Oguro et al., 2010; Park et al., 
2003) and this protein has been found to regulate self-renewal of HSC (Iwama et al., 2004) 
CBX family members were found to regulate balance between self-renewal and 
differentiation during hematopoiesis (Klauke et al., 2013). Loss of CBX2 leads to exhaustion of 
HSC and progenitors cells (van den Boom et al., 2013). CBX7 is necessary for HSC self-renewal 
(Klauke et al., 2013; van den Boom et al., 2013) and overexpression of this protein leads to 
enhanced expansion of hematopoietic progenitors (Klauke et al., 2013; Scott et al., 2007). 
7.2 Role in proliferation and differentiation 
RING1B, regulate cell proliferation during hematopoiesis and could act as positive or negative 
regulator (Calés et al., 2008). In vivo inactivation of this protein leads to hypocelularity of 
bone marrow (Calés et al., 2008) but also to reduced size of thymus and spleen (Raaphorst, 
Otte, & Meijer, 2001) Mice deficient in RING1B and their homolog RING1A suffer for aplastic 
anemia (Vidal & Starowicz, 2017) what is probably related to DNA replication in which both 
proteins are involved (Bravo et al., 2015; Piunti et al., 2014). Animals lacking CBX2 have 
hypoplastic lymphoid organs, defective expansion of T-cells and impaired differentiation of B-
cells (Coré et al., 1997; Iwama et al., 2004). Overexpression of CBX2 leads to enhanced 
differentiation (Iwama et al., 2004; Klauke et al., 2013). PCGF family members also plays role 
in proliferation and differentiation of hematopoietic cells. Loss of PCGF1 leads to 
enhancement of progenitor expansion (Ross et al., 2012; van den Boom et al., 2013). Lack of 
PCGF2 result in hypocellular bone marrow, spleen and thymus and also enhance proliferation 
of HSC (present in reduced number) (Park et al., 2003; Van Der Lugt et al., 1994). Loss of 
PCGF4 leads to enhanced lymphoid differentiation which is caused by activation of genes 
which control differentiation in this compartment and in normal situation are repressed by 
PCGF4 (Oguro et al., 2010). 
KDM2B regulates lineage commitment of HSC, loss of this protein results in defected 
lymphoid differentiation (Andricovich et al., 2016). BCOR deficiency leads to higher cell 
proliferation rate and enhanced myeloid differentiation (Q. Cao et al., 2016).  
Knockout of L3MBTL3 is embryonic lethal and impairs maturation of cell to granulocytes and 
erythrocytes (Arai & Miyazaki, 2005). Most of Polycomb function were investigated in HSC or 
progenitor/precursor cells, however in more differentiated cells these proteins also plays 
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fundamental role. Inactivation of Ring1A and Ring1B in lymphoid lineage results in block of T-
cells differentiation and conversion of these cells in functional B-cells (Ikawa et al., 2016). 
RYBP was found to regulate B-cell precursors differentiation (Calés et al., 2016).  
7.3 PRC1 in malignant hematopoiesis 
Considering how important role play PRC1 proteins in normal hematopoiesis, some groups 
also investigate their role in malignant situation. Deficiency of RING1B in absence of Ink4a 
products accelerates lymphomas (Calés et al., 2008) whereas in human progenitors lead to 
impaired leukemic transformation. Leukemic cells after loss of RING1B are incapable to 
maintain transformed phenotype (van den Boom et al., 2016). LSC which do not express 
PCGF4 lost capacity of self-renewal and are going to apoptosis (Lessard & Sauvageau, 2003; 
Rizo, et al., 2008). CBX family member also were found to regulate leukemogenesis, 
overexpression of CBX7 cause T lymphomas (Klauke et al., 2013) and CBX8 is necessary for 
initiation and maintenance of leukemic cells (Tan et al., 2011). Deficiency of CBX8 in 
transformed cells results in their impaired expansion (Maethner et al., 2013) and also in 
induce their differentiation (Beguelin et al., 2016). 
KDM2B and BCOR were found to be essential factor for induction of leukemogenesis and also 
for maintenance of leukemic cells. Overexpression of KDM2B leads to leukemia in mice 
(Andricovich et al., 2016; Ueda et al., 2017).  
 
As a starting point in our attempt to evaluate whether the established knowledge of PRC1 
holds in primary cell types or derived from them after ex-vivo expansion we focused on a 
PRC1 subunit that was common to all complexes. Only two candidates appeared the pair of 
paralogs RING1A and RING1B. We chose RING1B, given its larger functional impact (see 
above). We managed to get hold on a mouse model that expressed a form of tagged-RING1B 
that, on paper, looked ideal for our purposes. The reason is that such a RING1B modification 
was achieved by knocking-in the tag, through homologous recombination. In this way, 
regulation and expression of the tagged variant would be as close as they get to physiological 
RING1B levels. The tag, a short sequence biotinylated in vivo, was advantageous because 
allowed for efficient isolation by using immobilized streptavidin, a system previously used in 
the laboratory (Sánchez et al., 2007). This set up was used to investigate RING1B-containing 
assemblies, with a focus on Polycomb complexes in hematopoietic cells.
  
 
  
Objectives 
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OBJECTIVES 
 
1. To characterize expression levels and protein assemblies of PRC1 subunits in cell types with 
a defined (hematopoietic) cell lineage. 
 
2. To identify PRC1 subunits present in RING1B complexes in primary, ex-vivo expanded and 
immortalized hematopoietic cell types. 
 
3. To explore the role of RING1A and RING1B in the stability of PRC1 assemblies.  
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MATERIALS AND METHODS 
1. Mouse models 
BirA - This mouse line carries a cDNA encoding the E. coli biotin ligase BirA inserted into the 
Rosa26 locus, a transcriptional unit of ubiquitous expression. It was kindly shared by Dr Koseki 
(RIKEN Center for Integrative Medical Sciences, Yokohama, Japan). We used mice 
homozygous for the insertion.  
Ring1Bbio - This mouse model carries a modified Ring1B locus in which a sequence encoding 
23 amino acids was inserted, through homologous recombination in embryonic stem cells, 
right before the stop codon of the Ring1B locus. It was also generated in Dr. Koseki’s lab. The 
C-term tag can be biotinylated by BirA in mice that combine the BirA and Ring1Bbio alleles, as 
shown in Fig. M1 
 
 
 
 
Ring1B fl/fl – This mouse line was designed in our laboratory by Dr Vidal as a model of 
conditional inactivation of RING1B. A modified Ring1B locus, Ring1Bfl in which an exon 
encoding sequences N-terminal to the RING finger is flanked by loxP sequences, leads to gene 
inactivation in the presence of Cre recombinase from P1 bacteriophage. The Ring1Bfl allele 
Figure M1. Controlled characterization of RING1B bound proteins in a close-to-physiological set up. (A) 
Genetically modified BirA mice, showing altered Rosa26 locus and, schematically, the RING1B product from 
wild type *Ring1B* locus. (B) Genetically modified Bird and Ring1Bbio mice showing altered Ring1B and 
Rosa26 loci. The biotinylated, tagged-RING1B expressed in these mice is also shown. (C) Representative 
western blot from total extracts prepared from spleen of mice of the indicated genotypes. 
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also contains a PGKneo cassette which, together with the floxed exon, is removed upon 
recombination (Calés et al. 2008). 
Mx-Cre - It is a transgenic lined in which a Cre recombinase cDNA, fused to elements of the 
Mx-1 promoter responsive to the interferon signaling pathway, is used to drive Cre activity in 
(predominantly) hematopoietic bone marrow cells (Gu et al., 1994). These mice were crossed 
with Ring1fl/fl animals for inducible (after Polyinosinic-polycytidylic acid, p(I:C) injections) 
inactivation of RIng1B in vivo. The structure of p(I:C) mimics a double stranded RNA as in viral 
infections that trigger an interferon response. 
CreERT2 – In this mouse line a hybrid cDNA encoding a Cre recombinase fused to the ligand 
binding domain of the human estrogen receptor, is inserted in 3’-UTR sequences of the 
Polr2a gene (Mijimolle et al., 2005). Expression of the Cre-ERT2 recombinase is ubiquitous but 
its activity can be regulated by the estrogen analog, 4’-hydroxytamoxifen (4’-OHT) that 
induces its translocation to the cell nucleus and its relocation to the cytoplasm in the absence 
of 4’-OHT. Mice homozygous for Ring1Bfl and CreERT2 were used as a source of cells for 
studies in vitro that required Ring1B inactivation. 
Ring1A-/- –. A mouse line carrying a deletion of most coding exons of the Ring1A locus, i.e. a 
null mutation, reported by our laboratory (del Mar Lorente et al., 2000).  
Ring1A-/- Ring1Bfl/fl CreERT2 – Mice carrying the indicated alleles were generated by 
successive mattings. These mice were a source of cells for the compound inactivation, in vitro, 
of Ring1A and Ring1B genes. 
2. Isolation of genomic DNA 
A crude preparation of genomic DNA was prepared from a biopsy of small part of tail from 21 
day age mice. Tissue was lysed in 50mM Tris-HCl pH 8.0, 100mM EDTA, 100mM NaCl, 1% SDS 
containing  0.5 mg/ml Proteinase K (Roche) and incubated overnight at 550C. Most protein 
and detergent was precipitated by adding one third of a saturated solution of NaCl. After 
centrifugation in a microfuge, 10 min at 12,000 rpm the supernatant was transferred to a new 
tube. The DNA was then precipitated with 0.6 volumes of isopropanol and isolated by 
centrifugation during 10 min at 40C. The pellet was washed with 70% EtOH, air-dried and 
resuspend in TE buffer. 
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3. Genotyping by PCR 
DNA was diluted 1/10 with water and 1 µl used per reaction. Oligonucleotides (Table 1) were 
purcharsed from Sigma. All reagents used for PCR reactions were purchased from Biotools. 
Polymerization reactions were carried out in a Thermocycler T300 (Biometra). 
cDNA Sequence 5’-> 3’ Size of product PCR conditions 
birA::Rosa26 TGTTGCAATACCTTTCTGGGAGTTC 311 bp 940C x 30 sec 
600C x 30 sec 
720C x 30 sec 
 
X 32 cycles 
GTCCTCCTCCGAGATAAGCTTCTG 
Rosa26 TGTTGCAATACCTTTCTGGGAGTTC 528 bp 
AGAAGGAGCGGGAGAAATGGATATG 
Ring1B-bio GCACCCACCAAGGAGCAC  
 
1500 bp (1400 
wt) 
940C x 45 sec 
600C x 45 sec 
720C x 1min 30 sec 
 
X 34 cycles 
AATCTTATGGCACAGATTAC 
 
 
4. In vivo Ring1B inactivation 
Inactivation of Ring1B in vivo was attained by intraperitoneal injection of 8.5mg/kg p(I:C) (GE 
Healthcare) on three alternate days in 10- to 20-week-old mice. As a control we used animals 
without the Mx-Cre transgene injected with p(I:C) as well. Tissues were used two months 
after p(I:C) injection so that recombination in peripheral organs could be achieved. Effective 
inactivation was tested by Western blot. 
5. In vitro Ring1B inactivation 
Cultures of Ring1Bfl/fl CreERT2 or Ring1A-/-, Ring1Bfl/fl CreERT2 cells were given 0.5 µM 4’-
OHT(Sigma) from a stock solution in ethanol (EtOH), during 16 hours. After this time, cells 
were centrifuged and fresh medium added, in order to minimize undesired effects associated 
to the continuous presence of the Cre recombinase within the cell nucleus. Usually, RING1B 
Table 1. Primers and PCR reactions conditions used for genotyping 
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levels decreased dramatically within 36-48 hours after treatment. As a control, cells of the 
same genotype received an equivalent volume of EtOH. 
All mouse procedures were institutionally approved and were performed in accordance with 
national and European regulations. 
6. Tissue culture cel l  l ines 
293 PlatinumE  - It is a retroviral packaging cell line based on the human kidney embryonic 
293 cell line. These cells contain genes codifying for viral structure proteins (gag, pol and env) 
under control of EF1α promoter (Morita, Kojima, & Kitamura, 2000) 
293 BirA-bioRING1B – Clones of 293T cells transfected, sequentially, with plasmids that confer 
expression of BirA ligase and of a tagged-RING1B variant that can be biotinylated were 
generated by standard procedures.  
7. Purification of murine hematopoietic cel ls 
7.1 Immature, l ineage negative cel ls (Lin-) 
They were purified using mouse Lineage Depletion Kit (Miltenyi Biotech) according to 
manufacturer protocol. In brief, bone marrow was harvested from femurs, tibias and hips of 
10- to 20-week mice. Cells were filtered and antibody cocktail was added to the suspension. 
After 15 minutes of incubation, cells were washed and secondary antibody was added for 10 
minutes. After antibody binding and subsequent washes, cells suspensions were passed 
through LD column and Lin- cells were collected in the flowthrough. When used in 
transduction experiments, 2,5x104 cells per well, were seeded in 24-multiwell non-treated 
tissue culture plates (Costar) in IMDM containing 15% fetal calf serum (FCS), 10 ng/m IL-6 
(Immunotools), homemade IL3 (10% of WEHI-conditioned medium) and 5% of homemade 
SCF (conditioned medium of CHO SCF-expressing cell line). 
7.2 Pr imitive, CD117 (c-kit) positive cel ls 
Cells were purified using mouse CD117 MicroBeads (Miltenyi Biotech) according to 
manufacturer protocol. In brief, bone marrow was harvested from femurs, tibias and hips of 
10- to 20-week old mice. Cells were filtered and beads were added to the cell suspension. 
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After 15 minutes of incubation, cells were washed and passed through LS column. For 
transduction purposes, c-kit+ cells were seeded 2,5x105 cells per well in a 24-multiwell plates 
in the same medium as indicated for Lin- cells. 
8. Retroviral  transduction of hematopoietic cel ls 
Viral particles 
293 PlatinumE cells were seeded the day before transfection at density 3x106
 
cells per 10 cm 
dish. 10 µg of plasmid complexed with TurboFect (Biotools) was added to the cells, and after 
16 hours, cells were fed fresh medium. Supernatant containing virus particles were collected 
after 48, 60 and 72 hours. After filter-sterilization, aliquots were stored frozen at -80ºC. Viral 
titers of the various preparations were estimated either by cytometry analysis of GFP 
expression (encoded by the viral genomes) or counting colonies of puromycin- or neomycin-
resistant 3T3 cells. 
Hematopoietic cells were pre-stimulated during 24 hours in 1ml of medium containing 
cytokines, in order to obtain a highly proliferative population. Then, 750µl medium was 
removed and replaced with viral supernatant containing polybrene at a final concentration of 
2 µg/ml. Subsequently, cells were centrifuged at 800 x g in A-4-62 rotor (Eppendorf) during 1 
hour at room temperature. After centrifugation, 750 µl of medium was replaced by fresh 
medium containing cytokines. This procedure was repeated 24 hours later. 
9. Immortal ization/transformation of hematopoietic cel ls 
Two processes, displayed schematically in Fig. M2, were used.  
We used the overexpression of a protein in which the N-term of Nup98, a nucleoporin often 
found translocated in hematological disorders is fused to the DNA binding domain of HOXA10. 
The cDNA, a gift of R.K. Humphries (Terry Fox Laboratory, Vancouver, Canada) was subcloned 
into a retroviral plasmid that uses as control elements the mouse stem cell virus LTR (pMSCV). 
After two rounds of spinoculation-transduction, bone marrow Lin- cells were selected in 1,5 
µg/ml of puromycin (TOKU-E). 
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9.1 Immortal Lin- cells  
After 4-5 days of antibiotic selection, the medium was replaced and cells were seeded at a 
density of 0,2x106cells/ml. Cultures were splitted every 2 days. Sixteen days after first round 
of transduction, the culture was considered immortalized and cell stocks prepared by freezing 
aliquots in FCS containing 10% DMSO (Sigma). Successful thawing up was an indication of 
immortalization. 
9.2 Immortal, transformed myeloid progenitors 
We followed a classical protocol developed to generate cells used for in vivo models of acute 
murine leukemia (AML)(Somervaille & Cleary, 2006). Isolated c-kit+ cells were transduced 
with pMSCV-MLL-AF9 (kindly provided by J. Hess, Indiana University School of Medicine, 
Indianapolis). After 2 rounds of spinoculation, cells were plated in methylcellulose (M3231, 
Stem Cell Technologies) containing 20ng/ml of IL-3 (Immunotools), 5% of homemade SCF, 10 
ng/ml IL6, 10 ng/ml GM-CSF (both from Immunotools) and 0.75 mg/ml of G418 (Gibco), at a 
density of 104 cells per well in 24 multi-well plate. After 6 days, methylcellulose was dispersed 
and cells replated at the same density but in medium without G418. Five days later, colonies 
were replated one more time, but at a density of 5x103 per well. After this third round, single 
colonies were plucked from methylcellulose and transferred, individually, to RPMI1640 
medium (Biowest) containing 20% of FCS, IL3 (20% of WEHI-conditioned medium), IL-6, 10 
ng/ml, and 5% of homemade SCF. Three days later, cultures derived from single colonies were 
Figure M2. Immortalization/transformation of hematopoietic progenitors. The indicated retroviruses were 
introduced in bone marrow progenitors (Lin- and c-kit+).Representative images of Nup98-HD10-immortalized 
cells (top) and a colony of Mll-Af9-transformed cells growing in methyl cellulose are shown. 
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transferred to 24-well plates and after 48 hours, actively growing cultures were pooled. As 
above, cell stocks were stored frozen at -80ºC and immortalization was assessed by ability to 
successful growth after several freezing-thawing rounds. 
10. Isolation of pr imary cel ls from spleen ant thymus 
Tissues were harvested and smashed in 40 µm cell strainer (Falcon) in cold PBS. Suspension 
was centrifuged for 10 minutes at 400 x g in A-4-62 rotor (Eppendorf) at room temperature. 
Cell pellet was resuspended in 2 ml of ACK lysis buffer (150mM NH4Cl, 10mM KHCO3, 0.1 mM 
Na2EDTA, pH 7.2-7.4) and left for 1 minute at room temperature to remove erythrocytes. The 
tube was then filled up with 13 ml of PBS, mixed and centrifuged for 10 minute at 400 x g in 
A-4-62 rotor (Eppendorf) at room temperature. Cell pellet was washed with PBS twice to 
remove erythrocytes debris and used for protein extracts preparation. 
11. Generation of murine bone marrow-derived macrophages 
Bone marrow from 10- to 20 week mice was harvested in DMEM (Biowest) containing 10% of 
FCS and 50µM 2-mercaptoetanol (Sigma) and filtered through 40 µm cell strainer. After 
centrifugation at 400 x g for in A-4-62 rotor (Eppendorf) 10 min at room temperature, cell 
pellet was resuspended in 1 ml of ACK lysis buffer and incubated for 1 minute. Then tube was 
filled up to 20 ml with PBS, mixed and centrifuged at 400 x g in A-4-62 rotor (Eppendorf) for 
10 min. Cells were resuspended in 14 ml of RPMI 1640 medium and divided into two 10-cm 
petri dishes. Next day no attached cells were collected and seeded in 9 cm bacterial plates at 
density 1x106 cells/ml, with 7ml per plate. hrM-CSF (Immunotools) was added to each plate to 
final concentration 5µg/ml. This procedure was repeated at days +3 and +5. At day +7 cells 
were recovered from plates and used for further analysis. 
12. Isolation of bone marrow neutrophi ls 
Purification of neutrophils was done by Percoll gradient (Amersham Pharmacia Biotech, 
Uppsala, Sweden) as described previously (Boxio et al., 2004). In brief, bone marrow cells 
were flushed from bones with Hanks’ balanced saline solution (HBSS – without calcium, 
magnesium and phenol red) containing 15mM EDTA, centrifuged at 400 x g for in A-4-62 rotor 
(Eppendorf) 5 min and resuspended in 1ml of HBSS-EDTA. Cells were laid on top of a three-
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layer Percoll gradient, of 78%, 69% and 52% densities, prepared by diluting 100% Percoll with 
HBSS. Cells were centrifuged at 1500 x g for 30 minutes at room temperature without brake. 
The neutrophils from the 69%/78% interface and the top of the 78% layer were harvested 
and washed twice with 2 ml of PBS. Morphology of cells was checked by May-Grunwald-
Giemsa (MGG) staining, confirming purity of isolated cells (≥ 95%). 
13. Purification of murine Ter119 and CD19 positive cel ls  
Cells were purified using mouse Ter119 and CD19 MicroBeads (Miltenyi Biotech) according to 
manufactured protocol. In brief, bone marrow was harvested from 10- to 20-week mice. Cells 
were filtered and beads were added to the cell suspension. After 15 min of incubation, cells 
were washed and passed through LS column. Eluted cells were used for loading buffer 
extract. 
14. Activation of splenocytes with l ipopolysaccharide (LPS) 
Splenocytes were harvested and resuspended in 10 ml of RPMI1640 with 15% of FCS and 
50µM 2-mercaptoetanol. 2,5 ml of Ficoll Histopaque (GE Healthcare) was layered at the 
bottom of the tube. Sample was centrifuged at 800 x g in A-4-62 rotor (Eppendorf) for 10 min 
at 200C without brake. Obtained buffy coat in interphase, containing splenic cells was 
recovered and washed with 5 ml of medium. Cells were counted and seeded at density 
4x105/ml in medium containing 10µg/ml LPS (Sigma). After 72 hours cells were harvested and 
used for further experiments. 
15. Cytometry analysis of hematopoietic cells 
 
For the phenotypic analysis of hematopoietic progenitors, cells were resuspended in staining 
buffer (PBS with 2% of FCS and 0.01% sodium azide) and blocked for 5 min in 40C with anti-
mouse BD Fc Block (Becton Dickinson). Subsequently cells were centrifuged at 300 x g in A-4-
62 rotor (Eppendorf) for 5 minutes and further incubated for 20 min with appropriated 
antibodies conjugated with different fluorochomes. All antibodies used were purchased from 
Becton Dickinson: anti-CD117 (ckit, 2B8)- phycoerythrin (PE), anti-CD11c (Mac-1, M1/70)-
peridinin chlorophyll protein (PerCP)-Cy5.5, anti-Sca1(D7)-PerCP-Cy5.5, anti- Gr1 (RB6-8C5)-
biotin. After labelling, cells were washed with staining buffer and centrifuged. Cells stained 
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with antibodies conjugated with biotin were subsequently incubated with streptavidin 
conjugated with PE for 10 min at 40C and washed with staining buffer. Fluorescence-activated 
cell sorter (FACS) analysis from 5,000 to 10,000 cells was performed on a FACScan instrument 
(Becton Dickinson). Data were analyzed with FlowJo software v.8.8.6 (Tree Star, Ashland,OR). 
16. Loading buffer  extracts 
Cells were lysed in Laemmli buffer with protease inhibitors for 5 min at 95oC and sonicated 
with a Bioruptor Diagenode. Lysates were cleared from cell debris by centrifugation at 11,000 
x g for 10 minutes in I6F24-11 rotor (Eppendorf). For protein levels analysis, volume 
equivalent to 2x105 cells was used. 
17. Nuclear  extracts  
Cells were harvested and washed with ice-cold PBS and centrifuged for 5 minutes at 400xg. 
Cells were resuspended in 5 volumes of ice-cold buffer A (10mM HEPES-KOH pH7.9, 1.5mM 
MgCl2, 10mM KCl, 0.5mM DTT supplemented with protease (Biotools) and phosphatase 
(PhosStop, Roche) inhibitors, and incubated on ice for 10 minutes. Suspension was 
centrifuged for 5 minutes at 400 x g in A-4-62 rotor (Eppendorf) at 40C, and subsequently, 
pellet was resuspended in 2 volumes of buffer A with added 0.15% Igepal. Suspension was 
then transferred to a Dounce homogenizer and cells were homogenized with pestle type b 
with break every 10 strokes. Efficiency of nuclei isolation was checked with Trypan Blue 
(Sigma). Nuclei suspension was transferred to a new tube and centrifuged for 15 minutes at 
3200xg at 40C. Supernatant was discarded and 5 volumes of ice-cold PBS were gently added 
to the pellet. Pellet was detached by flicking tube a few times and then centrifuged for 5 
minutes at 3200xg at 40C. Supernatant was discarded and nuclear pellet resuspended in 2 
volumes of buffer C (420mM NaCl, 20 mM HEPES-KOH pH7.9, 20% glycerol, 2mM MgCl2, 
0.2mM EDTA, 0.1% Igepal, 0.5mM DTT, protease and phosphatase inhibitors). Suspension was 
incubated at 40C on rotating wheel for 60 minutes and subsequently centrifuged at 11,000 x g 
at 40C I6F24-11 rotor (Eppendorf) for 40 minutes. Concentration of obtained nuclear extract 
was determined by Bradford assay. Extract aliquots were snap-frozen and stored at -800. 
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18. Binding to streptavidin beads (pul l  down) 
Nuclear extracts were transferred to low-binding tubes (Eppendorf), and salt concentration 
was adjusted to 150mM with HENG buffer (20 mM HEPES-KOH pH7.9, 20% glycerol, 
2mMMgCl2, 0.2mM EDTA, 0.1% NP40, 0.5mM DTT, protease  
 
 
and phospathase inhibitors). 5% of total protein was taken as input. Benzonase (Novagen) 
was added to diluted extract (250U/1mg of extract) Paramagnetic streptavidin beads 
(Dynabeads M-280, Invitrogen), 80 µl/mg of nuclear extract, were washed three times with 
HENG buffer and incubated with 1 hour at 4oC on a rotating wheel. The beads were washed 
differently depending on the cell type, as indicated in Table 1. Bound material was eluted by 
resuspension in Laemmli sample buffer and boiling of the suspension for 5 min at 96ºC. 
For mass spectrometry analysis, proteins were eluted from beads with 1% of SDS for 10 min 
at 95oC. Freshly prepared DTT was added to samples and further boiled for 2 min. Indol 3-
acetic acid (IAA) was added and were incubated for 30 min at room temperature in the dark. 
Finally, lithium dodecyl sulfate (LDS)-containing loading buffer was added, samples were 
loaded on Novex Bis-Tris gel (Invitrogen) and run for 20 min at 200V. Gel was stained with 
Colloidal Blue Staining Kit (Invitrogen), cut into pieces and liofilized for 4 hours. 
19. LC-MS/MS Analysis 
Peptide analysis by nano-LC-ESI-MS/MS with LTQ Orbitrap Velos (Thermo Fisher Scientific, 
Waltham, MA, USA) was performed as published follows: the instrument was coupled to 
Agilent 1200 HPLC nanoflow systems (dual pump with one precolumn and one analytical 
column; Agilent Biotechnologies, Palo Alto, CA, USA).  Data were acquired using Xcalibur 
Cell type Washes 
Splenocytes 3 times for 5 minutes with 0,25%  Igepal  and 0,1M NaCl 
Thymocytes 3 times for 5 minutes with 0,25%  Igepal  and 0,2 M NaCl 
Splenocytes + LPS 3 times for 5 minutes with 0,25%  Igepal  and 0,2 M NaCl 
Macrophages 3 times for 5 minutes with 0,25%  Igepal  and 0,2 M NaCl 
NUP98HD 3 times for 5 minutes with 0,1%  Igepal 
Table 2. Washes used in pull downs for each cell type. 
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(v2.1.0). HPLC solvents were as follows: solvent A consisted of 0.4% formic acid in water and 
solvent B consisted of 0.4% formic acid in 70% methanol and 20% isopropanol.  From a 
thermostated microautosampler, 8 μL of the peptide mixture was automatically loaded onto 
a trap column (Zorbax 300SB-C18 5 μm, 5 × 0.3 mm, Agilent Biotechnologies) with a binary 
pump at a flow rate of 45 μL/min using 0.1% TFA for loading and washing the precolumn.  
After washing, the peptides were eluted by back-flushing onto a 16-cm fused silica analytical 
column with an inner diameter of 50 μm packed with C18 reversed phase material (ReproSil-
Pur 120 C18-AQ, 3 μm, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). The peptides 
were eluted from the analytical column with a 27 min gradient ranging from 3 to 30% solvent 
B, followed by a 25 min gradient from 30 to 70% solvent B and, finally, a 7 min gradient from 
70 to 100% solvent B at a constant flow rate of 100 nL/min. The analyses were performed in a 
data-dependent acquisition mode using a top 15 CID method for the LTQ Orbitrap Velos. 
Dynamic exclusion for selected ions was 60 s. A single lock mass at m/z 445.120024 was 
employed. Maximal ion accumulation time allowed in MS and MSn mode was 500 and 50 ms, 
respectively. Automatic gain control was used to prevent overfilling of the ion trap and was 
set to 106 ions and 5000 ions for a full Fourier transform mass spectrometry scan and MSn, 
respectively. Peptides were detected in MS mode at 60 000 resolution (m/z 400).  
Protein Database Search 
The acquired raw MS data files were processed with msconvert (ProteoWizard Library 
v2.1.2708) and converted into Mascot generic format (mgf) files. The resultant peak lists was 
searched against the mouse SwissProt database version v2014.07_20141023 (24,862 
sequences, including isoforms as obtained from varsplic.pl) with the search engines Mascot 
(v2.3.02, MatrixScience, London, U.K.) and Phenyx (v2.5.14, GeneBio, Geneva, 
Switzerland). Submission to the search engines was via a Perl script that performs an initial 
search with relatively broad mass tolerances (Mascot only) on both the precursor and 
fragment ions (±10 ppm and ±0.6 Da, respectively). High-confidence peptide identifications 
were used to recalibrate all precursor and fragment ion masses prior to a second search with 
narrower mass tolerances (±4 ppm and ±0.025 Da). One missed tryptic cleavage site was 
allowed. Carbamidomethyl cysteine and oxidized methionine was set as a variable 
modification. To validate the proteins, Mascot and Phenyx output files were processed by 
internally developed parsers. Proteins with ≥2 unique peptides above a score T1 or with a 
single peptide above a score T2 were selected as unambiguous identifications. Additional 
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peptides for these validated proteins with score >T3 were also accepted. For Mascot and 
Phenyx, T1, T2, and T3 were equal to 16, 40, 10 and 5.5, 9.5, 3.5, respectively (p value <10–3). 
Following the selection criteria, proteins were grouped on the basis of shared peptides, and 
only the group reporters are considered in the final output of identified proteins. Spectral 
conflicts between Mascot and Phenyx peptide identifications were discarded. The whole 
procedure was repeated against a reversed database to assess the protein group false 
discovery rate (FDR). Peptide and protein group identifications were <0.1 and <1% FDR, 
respectively 
20. Glycerol  gradients 
For glycerol gradient analysis, 500 µg of nuclear extract was added to the top of 4 ml 15-35% 
gradient. The sample was then centrifuged at 35,000 rpm at 40C for 16 hours in a SW55Ti 
rotor (Beckman). Gradient was then fractionated every 180 µl. Four volumes of cold acetone 
(-200C) were added and thoroughly mixed by vortexing. Protein was then precipitated for 2 
hours at -200C and subsequently centrifuged at 11,000 x g at 40C I6F24-11 rotor (Eppendorf) 
for 10 minutes. Supernatant was removed and protein pellet was air dried at room 
temperature. Dry pellets were resuspended in Laemmli sample buffer and resolved on SDS-
PAGE gels.  
21. Western blotting analysis 
Proteins were subjected to SDS-PAGE and transferred to nitrocellulose membrane 
(Amersham Protran, GE Healthcare) on a wet transfer apparatus (Bio-Rad). After blocking in 
5% nonfat dry milk (Blotto, Santa Cruz Biotechnology) in Tris-buffered saline containing 0.1% 
Tween20 (TTBS), filters were incubated with primary antibodies diluted in blocking solution 
for 1-2 hours at room temperature. After three washes with TTBS, filters were incubated with 
horseradish peroxidase-conjugated secondary antibodies (Dako). Signals were detected using 
ECL Prime detection reagent (GE Healthcare). 
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22. Western blot quantification 
 
 
 
Only good quality Western blots were used for quantitative analysis. Chemiluminiscence 
signals were digitalized with a ChemiDoc Touch system (BioRad) and then analyzed with 
Image Lab 5.2.1 software (BioRad). Acquired signals were within the linear dynamic range of 
loading, to ensure responses to changes in amount of protein. Figure M4A shows variations of 
intensities obtained with different antibodies on serially diluted samples. In addition, the 
software allowed the identification of overexposed images, which turned red when 
containing saturated pixels (Fig. M3B). For normalization purposes, we used signals for 
histone H2A as a reference, except in pull-down experiments in which input (nuclear extract) 
signals were used. 
   
An important step during quantification was the account for background. We used a so-called 
rolling disc algorithm and a lane profile tool provided by the software for essential, careful 
background lane by lane subtraction. When employed side by side, it allows for an 
appropriate selection of band width and lane background for each lane. Using the "Lane and 
bands" tool, the band dimension and the volume under the peak were visualized two-
dimensionally (Fig M3C) and assisted in choosing a rolling disc value to perform the 
Figure M3. Western blot quantification. (A) Serial dilution of spleen extracts to show signal responses to 
variations in protein concentrations for the indicated antibodies.(B) Digital images showing signals 
appropriated (top) and saturated, useless (bottom) acquisition times. (C) Window of Image Lab 5.2.1 software 
to select values for band and rolling disc algorithm and (D) result of background subtraction. 
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background subtraction per band (Fig. M3D). Similar steps were carried out with 
normalization signals (normalization channel) with determine values that then are factored 
into the intensities computed for sample bands. To homogenize for experimental variation 
and antibody idiosyncrasy, samples were compared within stripes incubated with the same 
antibody.   
Analyses were carried out a minimum of two times (one exception indicated) with extracts 
prepared from independent cell preparations. Average values and standard deviation were 
plotted as bar graphs.                                            
23. May-Grünwald-Giemsa staining (MGG) 
Glass slides were covered with poly-L-lysine (Sigma) for 1 hour and air-dried. Cells were 
counted and resuspended in PBS at a density of 5x105/ml. For each sample, we used 5 x 104 
cells. After centrifugation in a Cytospin 3 device (Shandon), for 2 min at 800 rpm,  cells were 
fixed with methanol for 5 min and subsequently air-dried Slides with fixed cells were 
incubated with May-Grünwald (Sigma) solution for 5 minutes, washed with distilled water and 
incubated with Giemsa solution (Sigma) diluted 1:20 for 20 minutes. Slides were washed with 
distilled water, air-dried and inspected under microscope. Pictures were acquired with Zeiss 
Axiocam (Carl Zeiss, Inc). 
 
23. Antibodies used in this study 
Antibody source host clone 
RING1B Garcia et al. 1999 rabbit  
RING1A Schoorlemmer et al., 1997 rabbit  
CBX2 Schoorlemmer et al. 1997 rabbit  
CBX7 SCBT mouse G-3 
CBX8 Cell Signalling rabbit D2O8C 
PCGF4 Cell Signalling rabbit D242B3 
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PHC2 Kyoichi et al. 2013 mouse  
RYBP Garcia et al. 1999 rabbit  
YAF2 homemade rabbit  
PCGF1 SCBT mouse E-8 
KDM2B GeneTex (GTX104868) rabbit polyclonal 
SKP1 Abcam (AB10546) rabbit polyclonal 
PCGF5  Sigma (HPA038349) rabbit polyclonal 
DCAF7 homemade rabbit  
CKIIa  Cell Signalling (2656) rabbit polyclonal 
PCGF6 Thermo Scientific (PA5-35222) rabbit polyclonal 
L3MBTL2 Sigma (HPA000815) rabbit polyclonal 
H3 Abcam (AB1791) rabbit polyclonal 
H2A Milipore (07-146) rabbit polyclonal 
H2AK119ub   Cell Signalling rabbit D27C4 
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RESULTS 
1. Cellular models and PRC1 subunits studied 
The description of PRC1 subunits and ways in which they associated in hematopoietic cells 
constitutes the largest part of this study. We think it is convenient to use the classification of 
PRC1 complexes after Reinberg's lab (identified by their content in one or another member of 
the PCGF family) (Gao et al., 2012). We chose subunits for which reliable antibodies were 
available and that could tell about most of the canonical and non-canonical complexes (the 
less known of them, PRC1.3 was left out). Thus, beyond RING1A and RING1B, we analyzed 
PCGF4 and three of the CBX proteins to characterize canonical complexes; for non-canonical 
complexes, in addition to paralogs RYBP and YAF2, thought to be present in all of them, we 
studied PCGF1, KDM2B and SKP1 for PRC1.1, PCGF5, DCAF7 and CK2a for PRC1.5 and PCGF6 
and L3MBTL2 for PRC1.6 complexes. Fig. R1 shows the subunits investigated, as coloured 
components within accepted classes of PRC1 complexes. Why did we allocate CK2a in 
PRC1.5? In fact, based on its presence among proteins coimmunoprecipitated with CBX 
subunits (Vandamme et al., 2011) we could have also included it as a component of canonical 
PRC1 assemblies. However, although CK2a cannot be taken as a PRC1.5-specific subunit, we 
decided to refer to it as a PRC1.5 member because it is only there where some PRC1-related 
functionality, phosphorylating RING1B, has been reported for CK2a (Gao et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R1. Conventionally accepted PRC1 complexes, showing, in color, the component investigated in this 
study. 
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Some antibodies identified more than a single polypeptide. In three cases, at least, the 
possibility of translating alternate mRNAs has been documented and evidence for the 
existence of protein variants characterized. This is the case of the Kdm2b gene, known to 
encode long and short forms, depending on the presence/absence of 5’ exons in the 
corresponding mRNAs (see Fig. R2). The antibody used recognizes structures encoded by 
sequences in the common 3’ half of the mRNAs, explaining the identity of the two bands 
observed (Fig. R2A). For CBX7 and PCFG5, again, mRNAs predict the presence of, at least,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R2. Discerning products recognized by a subset of antibodies not showing univocal identification of 
antigens. Cartoons show schematic representations (not at the same scale) of intact (or truncated) the 
indicated genomic loci that could yield more than a polypeptide. Western blots on the right side show 
bands recognized by anti-KDM2B, anti-CBX7, anti-PCGF5 and anti-YAF2 antibodies in nuclear extracts (NE) 
and in extracts of transiently transfected (T) 293 cells expressing the indicated cDNAs. Figures on blots 
indicate molecular weight markers in kDa 
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two proteins both of which would have been recognized by the antibodies used. Since the 
mobilities in denaturing polyacrylamide gels of most PRC1 subunits departs from that 
expected from conceptual translation of sequences, we transfected Cbx7 and Pcgf5 cDNAs to 
try to correlate mobilities to known sequences. Both of our Cbx7 and Pcgf5 cDNAs encode for 
the long forms of CBX7 and PCGF5. Analysis of cells extracts from transfected cells showed 
that the long forms of either protein corresponded to the band of lower mobility recognized 
by anti-CBX7 and to the band of higher mobility labeled by anti-PCGF, respectively (Fig. 
R2B,C). We have no explanation for the identities of the second band in both cases, but a 
reassuring result was that the identified bands were the prevalent species associated to 
RING1B pull down experiments. 
 
 
 
 
 
Another protein for which we obtained two bands was YAF2. In this case, the only product 
predicted from known mRNAs would encode a very small polypeptide that would not be 
recognized by our antibody. As before, to make sure the identity of the visualized bands we 
Figure R3. Cellular models used in this work. Colors indicate type of analysis performed with every cell type 
as described in the legend 
 
 
 
 
70 
 
verified that the one of lower mobility was the product encoded for full length Yaf2 cDNA (Fig. 
R2D) Indeed, the expression of a Yaf2 cDNA identified the full, larger product, as the band of 
lower mobility, leaving no answer about the identity of the other band. In the opposite 
situation, we might have expected an additional species for PHC2 but it never appeared in our 
blots, possibly because the full-length form is expressed below detection levels in 
hematopoietic cells.  
 
To investigate PRC1 complexities we have used a variety of hematological cell types indicated 
in Fig. R3. Cells were derived from wild type mice or from any of the strains  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R4. Immunophenotype of expanded progenitors. (A)Representative flow cytometry plot of NUP98-
HD10-immortalized cultures labeled with the indicated antibodies; select populations containing Lin- cells are 
shown.(B) Labelled Mll-Af9 transduced cells showing a predominant population of c-kit, Gr1 and Mac1- 
expressing cells characteristic of transformed myeloid progenitors. Figures are mean values ± SD of 3 
determinations 
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mentioned in materials and methods section. Primary cells were as taken from the animal, 
pooled from several animals when if required to get enough numbers of them. Primary 
expanded refers to cells that underwent some time in culture, either to enrich (macrophages) 
or to obtain (proliferative splenocytes) specific cell types. Finally, in order to generate 
immortalized progenitors we used published strategies that provide enlarged populations 
that can be characterized by their surface markers. Nup98-HD10-immortalized cultures 
contain a mixture of undifferentiated (Lin-) and differentiated (Lin+, mostly expressing low 
levels of myeloid markers Mac1 and Gr1) cell populations (Ohta et al., 2007), which can be 
separated by immunodepletion techniques (Fig. R4A). Another immortalized cell population 
we used was that generated by transduction of the oncogenic Mll-Af9 fusion protein, which 
gives rise to cells used in murine models of AML, i.e. transformed cells of myeloid flavour 
(Fig.R4B) (Somervaille & Cleary, 2006). 
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2. Expression levels of PRC1 subunits in primary cells 
Our attempt to determine levels of select PRC1 subunits in hematopoietic cells was done by 
quantitative western blot. 
2.1 Primary cells 
We prepared cells suspension from selected bone marrow cells and secondary hematopoietic 
organs, spleen and thymus. B-cell progenitors and precursors were isolated by magnetic 
immunoisolation exploiting the expression of lineage-specific marker CD19. Likewise for 
erythroid precursors were we harvested bone marrow cells positive for Ter119.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R5. Relative levels of canonical PRC1 subunits in primary hematopoietic cells. Bars represent 
mean of two experiments ± SD. Values are referred to those in bone marrow Lin- cells (dashed line). 
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Neutrophils, instead were isolated by the physical properties that allow their enrichment in 
Percoll gradients (Boxio et al., 2004). To obtain enough cells, we used material pooled from at 
least 3 mice per B-cell and erythroid precursors, while enough cells could be obtained from a 
Figure R6. Relative levels of non-canonical PRC1 subunits in hematopoietic primary cells. Bars represent mean 
of two experiments ± s.d. Dashed line, as in Fig. 5, denotes level of the indicated protein in Lin- progenitors. * 
denotes, samples where signals were below detection. KDM2B values correspond to the combined contribution 
of both full-length and truncated forms, both of which associate with RING1B complexes, (see Fig.21B) while 
PCGF5 values are only those of the faster form, which is the one preferentially present in RING1B complexes 
(see Fig. 21C ). 
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Figure R7. KDM2B forms in hematopoietic cells. Figures  following description of cell type indicate ratios, as a 
mean ± SD of two experiments, of full length to truncated forms of KDM2B 
 
 
single mouse per neutrophils, splenocytes (high content in more differentiated B cells) and 
thymocytes. 
Total cell extracts, prepared as lysates in (denaturing) electrophoresis buffer, corresponding 
to 2 x 105 cells were used per lane. After western blot, signals were quantitated and 
normalized by content in histone H2A, as described above. Levels of PRC1 subunits in the Lin- 
population of immature bone marrow cells were used as reference, as shown in Figures 5 and 
6.  
Subunits of canonical PRC1 complexes were consistently found at the highest levels, but for a 
few exceptions, in the pool of Lin- cells (Fig. R5). Apart from PCGF4, PHC2, CBX7 and CBX8, 
that were present at hardly 15-30% excess in B-cell progenitors/precursors, all other subunits 
were at levels well below of those in Lin- cells (Fig. R5B, C). Of note, erythroid and above all 
myeloid (neutrophils) cells contained the lowest levels of PRC1 subunits.  
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, levels of both RING1 proteins were considerable lower in all cells tested, and 
with few exceptions, the lowest of al PRC1 subunits tested. (Figure R5A). 
This tendency towards reduced expression, compared to immature cells, was also seen 
among subunits of non-canonical complexes (Fig. R6). Exceptions, in all cell types, were YAF2 
and PCGF5 (Fig. R6A, D), which were seen at levels similar or higher than in Lin- cells. PRC1.5 
subunits were also present at low levels, except DCAF7 and CK2a in B-cell and erythroid 
precursors, respectively. It was notable the very high levels of YAF2 (3 fold-higher than in 
bone marrow progenitors) in spleen cells. (Fig. R6A). PRC1.6 subunit L3MBTL2 was below 
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detection in erythroid precursors and, as PCGF6, in neutrophils (Fig.R6B).  PRC1.1 subunits 
were also at low levels, in all cases, except KDM2B in erythroid precursors below those in Lin- 
cells (Fig. R6A). Regarding KDM2B, levels were calculated by combining the signals of the long 
and short forms, where they were present. For instance, levels of the full-length variant were 
below detection in primary cells from spleen and thymus. In general, the shorter KDM2B form 
was more abundant, except in macrophages (Fig. R7) which was also the only cell type where 
total (both forms) KDM2B levels were higher than in bone marrow progenitors. 
 
 
 
 
 
Figure R8. Relative levels of canonical PRC1 subunits in ex-vivo expanded hematopoietic cells. Bars 
represent mean of two experiments ± SD. As before, the reference is values in Lin- cells. 
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2.2 Expanded primary cells 
All cells expanded ex vivo showed increased levels of PRC1 subunits compared to primary 
cells (Fig. R8 and R9). Canonical PRC1 subunits were found always at higher than those in 
primary cells, often higher than those in bone marrow Lin- cells (Fig. R8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R9. Relative levels of non-canonical PRC1 subunits in ex-vivo expanded hematopoietic cells. Bars 
represent mean of two experiments ± SD. Values in Lin- cells are shown as a reference. 
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RING1B, CBX2, CBX7 and PCGF4 were consistently present at higher levels but the content in 
these subunits was very variable between cell types. Examples are PCGF4 in Nup98-HD10-
immortalized cells or CBX8 in macrophages (Fig. R8B, C). Non-canonical PRC1 subunits were 
found also at higher levels than in primary cells, in the same heterogeneous fashion with 
some cell types expressing very high levels (RYBP,SKP1 or DCAF7, Fig. R9). 
For easy of comparison, the big differences in contents of RING1A and RING1B proteins in 
primary vs ex-vivo expanded cells is shown in Fig. R10. 
Possibly a reason for higher PRC1 levels in expanded versus primary cells is the distinct 
metabolic status associated to the active proliferative state. In vitro culture effects were 
maintained to a minimum by analyzing cells at the shortest possible time: 3 or 7 days 
 
 
 
 
 
(LPS- stimulated splenocytes, macrophages, respectively) and 2-3 weeks for cells undergoing 
immortalization.  
To test this notion we chose the best pairs of cell types that could be compared. On the one 
hand, spleen cells (close to a quiescent population) and proliferative cells derived from them 
after LPS-induced stimulation (Figs. 11A and 12A). On the other, the proliferative (Lin-) and 
Figure R10. Levels of RING1A and RING1B in primary and expanded cells. Bars represent mean of two 
experiments ±s.d. Signals are normalized by H2A content. As reference were used levels in lin- cells from 
bone marrow (BM) which protein levels was considered as =1 and is marked with grey line in all plots. 
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non-proliferative (Lin+) populations within cultures of Nup98-HD10-transduced progenitors 
(Fig. R11B and 12B). The data showed that, almost with no exception, levels were higher for 
proliferative cells, whether for canonical (Fig. R11) or non-canonical (Fig. R12) PRC1 subunits. 
 
  
Figure R11. Comparison between levels of canonical PRC1 subunits levels within comparable 
quiescent/proliferative cell types. 
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3. Diversity of molecular species containing PRC1 subunits 
The biochemical nature of chromatin regulator complexes usually is given by the 
identification of components within purified preparations. Traditionally, in protein isolation 
procedures, this has been achieved by following an enzymatic activity. However, with 
exceptions, such as the isolation of PRC1 complexes with histone H2A monoubiquitylation 
activity, this has not being always the case for chromatin regulator complexes. Instead, two-
step affinity purification schemes have been used, followed by mass-spectrometry/western 
Figure R12. Comparison between levels of non-canonical PRC1 subunits levels within comparable 
quiescent/proliferative cell types. 
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blot identification. Whereas this may yield preparations relatively free from non-related 
subunits, it certainly does not resolve different species of complexes. 
 
3.1 Complexes with RING1A and RING1B 
To gain insight in the possible intricacies of PRC1 complexes, we decided to analyze the 
behavior of nuclear extracts in density gradients of glycerol (15% to 35%). At the equilibrium, 
fractions were taken and orderly analyzed by Western blot. Obviously the resolution power of 
this method is not ideal but it combines simplicity with the ability to provide a great deal of 
information. Another important consideration: there is no way to derive quantitative 
relationships in this analysis because western blot signals are not comparable for different 
antibodies. Thus, PRC1 subunits present at low concentrations may not appear as such just 
because acquisition times of chemiluminesce was that sufficient to provide an image. 
Moreover, it is not only the amount of the different proteins that influence the generated 
signal, but also the affinity/avidity of the antibodies used. For example, our anti-RING1B 
antibody was far more sensitive than anti-PCGF1 antibody (Fig M3). Despite the caveats, 
some relevant conclusions can be drawn for this analysis. 
 
Fig. R13 shows the results obtained for the distribution of RING1B and RING1A in the cell 
types indicated. Two simple observations are clear. First, each of these PRC1 subunits 
migrated within gradients as if belonging to very different molecular aggregates: RING1B in 
spleen extracts is found throughout most of the gradient (and RING1A in thymus extracts or 
Nup98-HD10 progenitors). Second, when considering high molecular weight species, it is 
RING1B rather than RING1A the subunits more abundant: a small part of RING1B was present 
in species migrating with densities as that of 440 kDa marker and above in primary cells from 
spleen and in cell expanded in vitro such as LPS-stimulated spleen cells and in macrophages 
(Fig. R13, left). In contrast, only very small amounts of RING1A were found in similarly sized 
species in spleen or thymus cells and in Nup-98HD10-progenitors (Fig. R13 right). Of note, the 
presence of high molecular weight species with RING1B did not correlate with proliferative 
states. 
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Thus, their residence in these complexes was clear in actively dividing cell types such as 
stimulated splenocytes or ex-vivo expanded macrophages but not so much in immortalized 
primitive and myeloid progenitors (Nup9-HD10, MllAf9-transduced). At the same time, 
samples enriched in quiescent primary cell types, spleen, thymus, contained large species 
with RING1B. (Fig. R13). 
3.2 Species containing subunits that associate competitively to RING1 proteins 
We then decided to compare the distribution of chromobox proteins and RYBP/YAF2 
paralogs, to see whether it could be perceived that their association to RING1A or RING1B 
was exclusive (schematized in cartoon R14C) (Tavares et al., 2012). When looking at CBX 
proteins (Fig. R14A) it was plain that, as seen for RING1A and RING1B, the allocation of each 
of these proteins varied with the cell type. Compare, for example, the CBX7-containing high 
molecular weight species in spleen and thymus cells (Fig. R14A middle). And, again, as seen 
above, there was no correlation between the presence of CBX proteins in large species and 
the proliferative status of the cell population analyzed: CBX8 in dividing but not quiescent 
spleen cells, while  absent from dividing immortalized cells (Fig. R14A right). Another 
interesting observation was that high molecular weight species in all cell types contain one (or 
Figure R13. Representative glycerol density mobilities of RING1B and RING1A-containing complexes in 
nuclear extracts from the indicated cell types. Every other fraction of the gradient analyzed are shown, 
marking (arrowhead) the one enriched in the marker protein of the molecular weight indicated. The red 
rectangle, in RING1A westerns, identify fractions containing large molecular assemblies. On the right side, 
the position of mobilities in electrophoresis of molecular weight markers. 
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more) CBX subunits: CBX7 in quiescent splenocytes, CBX2 and CBX8 in LPS-stimulated 
splenocytes and  
 
 
 
 
macrophages expanded in vitro. Perhaps exceptions were the immortal cell types, where 
large complexes were almost devoid of CBX proteins but for small amounts of CBX2 (Fig. 
R14A). 
The results for RYBP and its homolog YAF2 led to an unexpected observation: while smaller 
complexes contained either of them, YAF2, but not RYBP, was present in the largest species 
(Fig. R14B). Moreover, the intensity of signals in several cell types, suggested as if a large 
portion of total YAF2 was contained in the large complexes. As an exception, Mll-Af9-
immortalized myeloid progenitors were devoid of either RYBP or YAF2. About a possible 
alternative presence of either RYBP/YAF2 or CBX proteins (Tavares et al., 2012) in large 
molecular species the data are not conclusive (for instance, large complexes in immortalized 
myeloid progenitors lack both types of subunits). What the data point is at the coexistence of 
high molecular weight species containing CBX or YAF2. Assuming that most of YAF2 is part of 
Figure R14. Representative distribution in glycerol gradients of mutually exclusive RING1B/A interactors CBX (A) 
and RYBP/YAF2 (B). Schematic representation of expected binding competition in their association to the C-
term RAWUL domain of RING1 proteins. 
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PRC1 complexes it follows that large molecular PRC1 species are made of both canonical and 
non-canonical complexes. 
 
3.3 Complexes with canonical and non-canonical PRC1 subunits 
CBX proteins are considered genuine identifiers of canonical PRC1 complexes. However, there 
is at least a report in which CBX8 is found associated to BCOR-containing complexes (Beguelin 
et al., 2016), against the accepted consensus. Therefore, we chose to analyze the 
distributions in glycerol gradients of PCGF4 and PHC2, an interacting pair (Fig. R15B) which 
together make for good markers of canonical PRC1 complexes.  
 
 
 
 
PHC proteins, as described above, are proteins with shown capacity to generate large 
aggregates, due to the presence of dual interacting surfaces in their SAM domains. Thus, it 
was not surprising to see PHC2 as part of very large molecular species (spleen, thymus and 
dividing splenocytes (Fig. R15A, left). As part of smaller complexes was also seen in extracts of 
macrophages, but unexpectedly large complexes in immortal, undifferentiated progenitors 
Figure R15. Representative distribution in glycerol gradients of archetypical canonical PRC1 subunits PHC2 and 
PCGF4 (A) distribution in glycerol density gradient (B) schematic representation of PCGF4 contacting both 
RING1B and PHC2, although contacts between RINGB and PHC2 cannot be discarded 
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(expressing Nup98-HD10) lacked PHC2. PCGF4, on the other hand, was identified in fractions 
of the gradients corresponding to large species, although not always and not overlapping with 
fractions containing PHC2. For example, fraction 23 in dividing splenocytes have both PHC2 
and PCGF4, but the same fraction in extracts from macrophages while lacking PHC2 is 
enriched in PCGF4; similar discrepancy was also noticed in spleen and, most surprisingly in 
immortal, Mll-Af9-transduced myeloid progenitors (top and bottom rows in Fig. R15A). The 
accepted way of association of PHC2 and PCGF4 in PRC1 canonical complexes is as indicated 
schematically in Fig. R15B, i.e. PHC2-PCGF4 direct interaction determining its presence in 
canonical versus non-canonical complexes, and then through known contacts in PCGF4 with 
the RING finger of RING1A or RING1B. Therefore, the results suggest the existence, at least 
within the range of large sizes, of complexes of distinct content. Alternatively, PCGF4 and 
PHC2 in these extracts could be part of complexes not related to PRC1. 
 
 
 
 
Examination of distribution of PCGF members characteristic of non-canonical complexes (Fig. 
R16), as seen before with RYBP and YAF2 supported the existence of variously sized 
complexes, including some of very high molecular weight. PCGF6, originally described as part 
of a large complex in HeLa cells (Ogawa et al., 2002) only appeared to be present, partially, 
among large species in LPS-stimulated splenocytes. PCGF5 complexes, hardly studied, were 
found in fraction 23 of macrophages and immortal Lin- progenitors. The difficulty in 
interpreting these data considering the distribution of its direct interactions, RING1A and 
RING1B, is that whereas in macrophages RING1B co-fractionates, in immortal Lin- cells there 
are just minor amounts of RING1B or RING1A (Fig. R13). PCGF5 (leaving aside the band of 
lower mobility, of unknown identity, although it may well be a  
Figure R16. Representative distribution in glycerol gradients of the four PCGF subunits studied. 
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Figure R17. Representative distribution in glycerol gradients of subunits present in non-canonical complexes, 
PRC1.1 (A), PRC1.2 (B) and PRC1.6 (C). RING1A and RING1B (D) are shown for quick visualization of fractions 
that contain them. 
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posttranslational modified PCGF5, appears in large complexes of intermediate size (Fig. R16) 
complexes in macrophages and transformed progenitors, and as in other cell types.  
It was unexpected to find that non-canonical PCGF1 subunit appeared participating of 
aggregates larger, on average, than those containing canonical PCGF4 (Fig. R16, half left). 
Also, the presence of PCGF1 in very large complexes in some extracts is perplexing because 
none of them contain, for instance, its direct interaction KDM2B (Fig. R17A, left). And, as in 
other instances, there is no correlation with the presence of other direct interactions, namely 
RING1A and RING1B which are absent from these PCGF1 structures in cells like splenocytes or 
immortal Mll-Af9 progenitors (Figs. 13 and 16).  
Finally, subunits found in PRC1 complexes that appear to not bind directly RING1A or RING1B 
(SKP1, DCAF7, CK2a and L3MBTL2) were also studied (Fig. R17). Expectancies about obtaining 
useful information from these analysis were reduced, in part due to the the evidence of some 
of these proteins being part of non-PRC1 complexes (Hauri et al., 2016) 
Most CK2a was present in all cell types, except thymus and Mll-Af9 immortalized progenitors 
(Fig. R17B) large complexes, perhaps in the same molecular species that also contain RING1B 
and CBX subunits. The presence, also in high molecular weight complexes, of SKP1 in LPS-
stimulated spleen cells is difficult to associate to PRC1 species, because a hypothetical binding 
to RING1B would be mediated through KDM2B, which is absent from these same species  (Fig. 
17A, B). The migration of L3MBTL2 fits with that of PCGF6, except in the thymus, although 
only this evidence does not probe that they are part of the same complex(es).  
4. PRC1 subunits associated to RING1B  
As stated above, most studies reporting subunits in PRC1 complexes is not of quantitative 
nature. Whereas the identification of one or another component is valuable in itself, a more 
quantitative approach permits to speculate about the dynamics of the complexes. Indeed, 
more recent studies are undertaking such a quantitative approach using sensitive, although 
expensive mass-spectrometry methods. Here, we have identified PRC1 proteins associated to 
RING1B by quantitative western blot. We set up an in vivo tagging system for efficient 
isolation of RING1B expressed as close as possible to physiological levels. To do this, a 
sequence encoding a peptide that can be biotinylated was knocked in at the Ring1B locus by 
homologous recombination in ES cells, so that a fusion protein that is modified at its C-term 
was produced. Mice homozygous for this modification (Ring1B-bio/bio) were normal and 
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expressed a RING1B protein of lower mobility at levels similar to those in wild type mice (Fig. 
M1). Ring1Bbio/bio mice were mated to mice generated from ES cells where a cDNA 
encoding the E. coli BirA ligase was knocked into the Rosa26 locus, so that a ubiquitous biotin 
ligase activity on the sequence, 23 amino acids, at the C-term extension of RING1B was 
attained. Endogenously biotinylated RING1B, and associated proteins, were then isolated 
from nuclear extracts using immobilized streptavidin that shows a very high affinity for biotin. 
To control for non-specific associations we analyzed proteins bound to streptavidin in extracts 
that contain wild type, non-tagged RING1B. The animal models used for this study are 
depicted in figure M1. 
4.1 A way to estimate quantitative association to RING1B 
Experiments such as the isolation of a tagged protein and bound interactors are usually 
referred to as co-precipitation (co-immunoprecipitation if using an antibody) or pull-down 
experiments. For this study, we chose cells from spleen and thymus, proliferative splenocytes 
and macrophages from ex vivo expanded cultures as described above. As a source of primitive 
hematopoietic cells we chose the Lin- fraction from Nup-98HD10 immortalized progenitors.  
Pull-down experiments are critically dependent on conditions (protein concentrations, 
binding buffer and removal of non-specifically bound proteins with washes). An example with 
293 cells, an established human cell line widely used in the characterisation of protein 
complexes, including Polycomb complexes, is shown in Fig. R18. Here, a 293-cell clone 
selected after transfection of plasmids that express E. coli BirA and a biotinylatable RING1B 
variant was used. Note that this clone expresses amounts of ectopic, tagged-RING1B, 
comparable to those of the endogenous form (lane 5) which is efficiently captured by 
streptavidin beads (see the little remaining RING1B in not bound fraction, lane 6). Pulled 
down material from extracts that only expressed BirA provided the desired estimation of non-
specifically bound proteins. Lanes 3 and 4 illustrate how washing conditions can be found that 
eliminate background interactions by washes that modify ionic (NaCl) and hydrophobic 
environments (Igepal). At the same time tagged-RING1B and associated proteins after these 
washes, lanes 7, 8), although of similar appearance within the extremely limited number of 
binding event analysed, are expected to be free of non-specifically associated interactions 
after washes with 0.2M NaCl and 0.25% Igepal, lane 8, but not if washed with a buffer or 
reduced NaCl content, lane 7.  
88 
 
 
Using these conditions in pull down experiments with the indicated hematopoietic cells we 
observed somehow unexpected results. These are illustrated in Fig. R19A. Binding of a 
reduced number of PRC1 subunits to RING1B (in contrast to 293 cells, our hematopoietic cells 
express only the tagged-RING1B species) illustrates how proteins anticipated to be present as 
RING1B interactions, as seen with nuclear extracts from thymus cells (Fig. R19A, left) were 
missing among the material bound to streptavidin beads in extracts from spleen cells or 
primitive progenitors (Fig. R19 center, right). 
Obviously, conditions had to be found, if at all possible, that balanced the removal of non-
specifically bound material with the persistence of specifically bound proteins. We found that 
the conditions used for nuclear extracts from thymus were satisfactory too for macrophages 
and LPS-stimulated spleen cells. Figure R19B shows some of the results that lead us to identify 
conditions acceptable for spleen and progenitor cells. We took as controls of total binding the 
material present in not washed (quick rinse) beads. It can be seen that washes with only 
Igepal were not enough
Figure R18. Isolation of RING1B and associated proteins (pull down) in lines of 293 cells that express only biotin 
ligase BirA (293-BirA) or the biotinilytable RING1B form (BirA-RING1Bbio) under different conditions. 
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to remove background (PCGF6, CBX8 from spleen, Fig. 19B, lane 1), not even after increasing 
Igepal to 0.25% (not shown) and that some NaCl  had to be included in the washing buffer 
with inappreciable losses of specific binding (lane 1, 2 and lanes 3,4 of Fig. R19B). Pull down 
results with Nup98-HD10-progenitors illustrated how forcing washes lead to unacceptable 
results that remove much of the proteins bound, included those bound specifically. Thus, only 
Igepal washed background binding (lane 5) but conditions acceptable for spleen led to severe 
losses of specifically bound proteins (compare lanes 7 and 8 in Fig. 19B). Optimization of pull 
down experiments already allowed us to appreciate that the stability of proteins in the 
RING1B-containing complexes differed greatly among nuclear extracts. 
 
Once, those conditions for pull down experiments were defined we set out to analyze PRC1 
subunits bound to RING1B in the indicated cell types. Binding was plotted as a proportion of  
Figure R19. Optimization of streptavidin-pull down experiments with hematopoietic cells. (A) Conditions that 
are useful for tissue-culture, transformed cells (293) are unsuitable for hematopoietic cells. (B) Cell type-
dependent conditions to minimaze background binding. I, input (5% of total extract), NB, not bound fraction 
or proteins in extract after removal of strepatividin beads and associated proteins; B0, material eluted with 
loading buffer from beads after a quick PBS rinse, taken as not-washed beads. Eluted material, after 
indicated washes, is in lanes 1-8. 
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Figure R20. Canonical PRC1 subunits present in RING1B complexes in the indicated hematopoietic cell 
types. Values are the fraction of the total content in the extract that was removed upon incubation with 
streptavidin beads. That amount is the combination of material released from beads during washes and 
eluted after washes. Bars show mean values of two experiments ± SD. Inset in B is a western blot (I, input, 
NB; not bound and B, bound) showing association of the slow band recognized by our anti-CBX7. 
  
 
  
 
 
 
 
 
 
 
91 
 
the protein present in the extract. Our quantitative approach was as follows: total content of 
the protein of interest was calculated from the intensities of signals of a small portion (5%, or 
input). Then we estimated the fraction of total binding from the difference between the 
signals for input and not bound fractions (volume of extract, after incubation with 
streptavidin beads, equal to that of input of the nuclear extract). It was clear that this amount 
was always larger than that deduced from signals of the material bound to beads after 
washes, the eluted fraction. The difference was called washed fraction. Thus, two magnitudes 
are plotted: eluted and washed fractions making the total of bound protein. The data are 
shown in Figs 20-23). Calculations were done on pixel values after subtracting signals derived 
from pull down with extracts made out of cells that do not express tagged-RING1B. The so-
called washed fraction contains not only protein genuinely washed but also not eluted and/or 
beads-trapped protein, most likely a small contribution that we decided not to correct for. 
Besides, as the Fig. 20 and 21 show, the differences among the magnitude of the washed 
fractions was too big as to be due to trivial reasons. Moreover, differences in the washed 
fraction also varied for the same protein. 
4.2 Striking differences within RING1B-bound PRC1 subunits and RING1B complexes within 
cell types 
Figures 20 and 21 display the data plotted by PRC1 categories, while Figures 22 and 23 
compare PRC1 subunits bound within a same cell type. The first observation is the highly 
efficient binding of tagged-RING1B, ranging from 65 to 90% of the total protein in the extract 
(Fig. 20A). Also, most of the protein remained after washes. All of which was expected given 
the high affinity of streptavidin for biotin.  
We found that most RING1A was not present among RING1B-bound proteins (maximum 
binding around 10-15%, most of which lost with washes, Fig R20A). This suggests, that most 
likely, PRC1 complexes containing RING1A and RING1B are separable entities. Among CBX 
proteins, it was CBX7, as a whole, the family member prevalent in RING1B complexes (Fig 
20B) and while some contained CBX8, the presence of CBX2 was almost negligible, or at least 
that of the fraction that resisted washes (Fig. 20B, right). Substantial amounts of canonical 
subunits PCGF4 and PHC2 were also found among RING1B-bound proteins, although the 
presence of PHC2 in ex vivo expanded cells was minimal (Fig. 20C). 
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Figure R21. Non-canonical PRC1 subunits present in RING1B complexes in the indicated hematopoietic cell 
types plotted as in Fig. R20. The inset in B shows differential binding of the full length or truncated KDM2B 
forms, depending on cell type, which is why the are shown separately. Note that bars indicate fraction of the 
total present and therefore, despite the larger proportion of full-length form bound, its contribution to total 
KDM2B is still below that of the, more abundant truncated form. Total binding is separated, as above, in 
washed and eluted fractions. 
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The presence of non-canonical PRC1 subunits as part of stably bound RING1B complexes was, 
in general low. In particular, the presence of RYBP or YAF2, two direct interactors of RING1B 
was was relatively minor (Fig. R21A), with less than a third of the protein available associated 
to RING1B. It was as if most PRC1 complexes in these hematopoietic cell types were to be 
made of canonical species. RING1B-PRC1.6 complexes, as assessed by the presence of PCGF6 
and L3MBTL2 (Fig. R21D) were poorly represented. Other direct interactors such as PCGF1 
and PCGF5, in contrast, were relatively enriched in RING1B complexes (Fig. R21B, C) but only 
in primary cells from spleen and thymus. It was unexpected to find the different affinities of 
KDM2B forms for PRC1 complexes in thymus cells, where despite the low concentration of 
the full-length form (Fig.R7 ) most of it was among proteins bound to RING1B (Fig. R21B).  
 
 
 
 
In contrast, in macrophages, where the full-length form is far more abundant, did not 
associate in an stable manner with the complex(es) (Fig . R21B ) 
Figure R22. PRC1 subunits bound to RING1B in primary hematopoietic cells. Plots as in Fig. R20. Proteins are 1- 
RING1B (1), RING1A (2), CBX2 (3), CBX7 (4), CBX8 (5), PCGF4 (6), PHC2 (7), RYBP (8), YAF2 (9), PCGF1 (10), full-
length KDM2B (11), truncated-KDM2B (12), SKP1 (13), PCGF5 (14), DCAF7 (15), CKIIa (16), PCGF6 (17), 
L3MBTL2 (18). 
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The above mentioned trends, that RING1B is present preferentially as part of canonical 
instead of non-canonical PRC1 complexes, and that PRC1 complexes are more easily captured 
from extracts from primary cells, can be seen in Figures R22, 23. Another singularity was that 
Figure R23. . PRC1 subunits bound to RING1B in primary in expanded hematopoietic cells. Plots as in Fig. R20. 
Proteins are 1- RING1B (1), RING1A (2), CBX2 (3), CBX7 (4), CBX8 (5), PCGF4 (6), PHC2 (7), RYBP (8), YAF2 (9), 
PCGF1 (10), full-length KDM2B (11), truncated-KDM2B (12), SKP1 (13), PCGF5 (14), DCAF7 (15), CKIIa (16), 
PCGF6 (17), L3MBTL2 (18). 
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PRC1.1 complexes were hardly present in ex-vivo expanded cells, where only PCGF1, but no 
KDM2B or SKP1, was found associated to RING1B (Fig. R23). Perhaps an extreme case was 
that of immortal immature progenitors (induced after Nup98-HD10 expression) were, apart 
RING1B, binding could be considered to occur mostly for PCGF family members (Fig. R21C). 
Overall, in many cases the association with RING1B complexes is rather labile and large part 
of the proteins initially bound, present at the beginning of washes, and are released 
eventually. Binding of L3MBTL in LPS-stimulated spleen cells (Fig. R23A) or of PCGF1 and 
PCGF5 in macrophages (Fig. R23B) are good examples.  
 
 
 
 
Since binding efficiency for many PRC1 subunits was below expectations we thought of a 
possible contradiction with published evidence about PRC1 complexes. Certainly, much of the 
reported data are seldom of quantitative nature. Therefore, we asked whether in our hands 
PRC1 assemblies captured from a "standard" cell type would differ from our data with 
primary of close-to-primary hematopoietic cell or, on the contrary, it would be that PRC1 
complexes might be more dissimilar between   cell types than anticipated. Thus, we carried 
out a quantitative estimation of the content of RING1B complexes in a subset of PRC1 
subunits in 293 cells. The data (Fig.R24) showed that binding was, in general, far more 
efficient than with nuclear extracts of hematopoietic origin, and that the washed fractions 
were relatively small, indicating a somehow stable association. In particular, the presence of 
non-canonical subunits in RING1B-assemblies was much more prevalent than that seen with 
hematopoietic cells. In summary, RING1B-PRC1 complexes are probably highly dynamic 
Figure R24. . PRC1 subunits bound to RING1B in a conventional tissue-culture cell lines. The proportion of the 
total protein for each of the indicated PRC1 subunits associated to RING1B is plotted as the mean value ± SD 
of two experiments. 
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entities whose levels, as well as the stability of the associations of their constituents vary with 
cell type. 
4.3 PRC1 and non-PRC1 RING1B-containing complexes.in thymus 
Similarly to our previous attempt at identifying RING1B interactors in MEL cells (Sánchez et 
al., 2007) and as part of forthcoming analysis of RING1B-bound proteins in hematopoietic 
cells, we identified interactors contained in thumus cells.  The main purpose of the inclusion 
of these (preliminary) results is to provide an idea of the network of interactions the core 
component of PRC1 complexes is involved in. Tables I and II display a list of proteins identified 
from the peptides contained in a pull down experiment as those described above. Spectral 
counts (a measure of mass), number of different peptides identified and extent of the protein 
covered by them are indicated. The lists are one of high stringency, in which proteins 
identified by peptides contained in control beads (material bound from extracts without 
biotinylated RING1B) were subtracted. Of interest here, a relatively large set of subunits of 
other chromatin regulators were present among RING1B interactors.  Some of them, 
commonly present in non-PRC1 complexes, were grouped, in table I, with PRC1 subunits on 
the basis of previous reports (Hauri et al., 2016; Trojer et al., 2011). 
It was interesting that many of subunits of chromatin remodelers of the SWI/SNF and NurD 
families were present almost in their entirety. Subsets of subunits are those in BAF 
complexes, the subtype of SWI/SNF complex containing ATP-dependent helicase 
BRG1/SMARCA4.  BAF complexes antagonize Polycomb activity (B. G. Wilson et al., 2010) and 
are involved in the eviction of PRC1 from chromatin (Stanton et al., 2016). The other 
remodeler whose components were enriched among RING1B interactors was NuRD, a 
complex with ability to rearrange nucleosomes and deacetylate their histones and has been 
shown to influence histone H3K27 status (Reynolds et al., 2012). Among DNA binding proteins 
the presence of Ikaros paralogs (IKZF1, 2 and 3) is probably relevant considering their activity 
targeting NuRD in lymphoid tissues (Yoshida & Georgopoulos, 2014). 
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Table I. Polycomb proteins associated to RING1B in thymus 
 
AC Gene symbol Protein UP SC COV 
Q9CQJ4 Rnf2 E3 ubiquitin-protein l igase RING2 9 88 0,29 
O35730-1 Ring1 E3 ubiquitin-protein l igase RING1 2 21 0,11 
P25916 Bmi1 Polycomb complex protein BMI-1 2 4 0,08 
Q64028-1 Phc1 Polyhomeotic-l ike protein 1 2 2 0,03 
Q9QWH1-1 Phc2 Polyhomeotic-l ike protein 2 4 4 0,04 
Q8CHP6-1 Phc3 Polyhomeotic-l ike protein 3 4 9 0,06 
P30658 Cbx2 Chromobox protein homolog 2 2 7 0,08 
O55187-1 Cbx4 E3 SUMO-protein l igase CBX4 6 8 0,11 
Q9DBY5 Cbx6 Chromobox protein homolog 6 1 1 0,05 
Q8VDS3 Cbx7 Chromobox protein homolog 7 5 9 0,27 
Q9QXV1 Cbx8 Chromobox protein homolog 8 11 30 0,35 
Q8CCI5 Rybp RING1 and YY1-binding protein 2 4 0,19 
Q99LW6-1 Yaf2 YY1-associated factor 2 1 3 0,13 
Q8R023 Pcgf1 Polycomb group RING finger protein 1 4 9 0,15 
Q6P1G2-1 Kdm2b Lysine-specific demethylase 2B 15 27 0,12 
Q8CGN4-1 Bcor BCL-6 corepressor 19 40 0,13 
A2AQH4 Bcorl1 BCL-6 corepressor-l ike protein 1 4 8 0,03 
Q9WTX5 Skp1 S-phase kinase-associated protein 1 4 6 0,25 
Q3UK78-1 Pcgf5 Polycomb group RING finger protein 5 5 14 0,22 
P61963 Dcaf7 DDB1- and CUL4-associated factor 7 5 9 0,13 
Q60737 Csnk2a1 Casein kinase II subunit alpha 3 4 0,08 
P67871 Csnk2b Casein kinase II subunit beta 3 4 0,12 
Q8R089 Fbrs Probable fibrosin-1 4 11 0,12 
Q6A4J8-1 Usp7 Ubiquitin carboxyl-terminal hydrolase 7 4 7 0,04 
Q99NA9 Pcgf6 Polycomb group RING finger protein 6 5 12 0,15 
P59178 L3mbtl2 Lethal(3)malignant brain tumor-like protein 2 4 13 0,06 
P23198 Cbx3 Chromobox protein homolog 3 3 7 0,14 
P61965 Wdr5 WD repeat-containing protein 5 3 5 0,11 
A2AWL7-1 Mga MAX gene-associated protein 21 34 0,09 
Q8BLB7-1 L3mbtl3 Lethal(3)malignant brain tumor-like protein 3 2 3 0,03 
 
 
 
 
 
 
 
 
 
Ac- accession number, UP- unique peptides, SC-spectral counts, COV-coverage 
Highlighted proteins were investigated during this study 
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Table II. Chosen non-Polycomb proteins associated to RING1B in thymus 
AC Gene symbol Protein UP SC COV 
    CHROMATIN REMODELLERS       
    SWI/SNF       
Q3TKT4-1 Smarca4 Transcription activator BRG1 11 32 0,08 
Q91ZW3 Smarca5 
SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily A member 5 13 30 0,13 
P97496-1 Smarcc1 SWI/SNF complex subunit SMARCC1 8 19 0,08 
Q8BSQ9-1 Pbrm1 Protein polybromo-1 9 16 0,06 
O54941 Smarce1 
SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily E member 1 3 9 0,1 
Q99JR8-1 Smarcd2 
SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily D member 2 4 8 0,11 
A2BH40-1 Arid1a AT-rich interactive domain-containing protein 1A 5 6 0,04 
Q61103 Dpf2 Zinc finger protein ubi-d4 1 1 0,04 
  
NuRD 
   Q6PDQ2 Chd4 Chromodomain-helicase-DNA-binding protein 4 23 57 0,13 
Q9R190 Mta2 Metastasis-associated protein MTA2 11 46 0,18 
Q60972 Rbbp4 Histone-binding protein RBBP4 9 35 0,21 
O09106 Hdac1 Histone deacetylase 1 5 35 0,12 
Q62318-1 Trim28 Transcription intermediary factor 1-beta 7 34 0,11 
Q60973 Rbbp7 Histone-binding protein RBBP7 8 26 0,19 
Q8VHR5-1 Gatad2b Transcriptional repressor p66-beta 10 24 0,22 
P70288 Hdac2 Histone deacetylase 2 4 24 0,12 
Q8K4B0 Mta1 Metastasis-associated protein MTA1 7 16 0,11 
Q8CHY6 Gatad2a Transcriptional repressor p66 alpha 6 10 0,14 
Q924K8-1 Mta3 Metastasis-associated protein MTA3 5 9 0,09 
Q09XV5-1 Chd8 Chromodomain-helicase-DNA-binding protein 8 2 2 0,01 
      Q03267-1 Ikzf1 DNA-binding protein Ikaros 12 44 0,25 
O08900 Ikzf3 Zinc finger protein Aiolos 7 33 0,16 
Q920B9 Supt16h FACT complex subunit SPT16 7 18 0,08 
P13864-1 Dnmt1 DNA (cytosine-5)-methyltransferase 1 9 17 0,06 
P81183-1 Ikzf2 Zinc finger protein Helios 3 9 0,05 
O88379 Baz1a Bromodomain adjacent to zinc finger domain protein 1A 3 3 0,03 
Q60520-1 Sin3a Paired amphipathic helix protein Sin3a 1 1 0,01 
HISTONE MODIFYING COMPLEXES 
Q80TJ7-1 Phf8 Histone lysine demethylase PHF8 3 9 0,04 
Q8VDF2-1 Uhrf1 E3 ubiquitin-protein l igase UHRF1 4 6 0,05 
Q8K224 Nat10 N-acetyltransferase 10 4 6 0,05 
B2RWS6 Ep300 Histone acetyltransferase p300 3 6 0,02 
Q9WTU0 Phf2 Lysine-specific demethylase PHF2 3 4 0,04 
Q5DW34-1 Ehmt1 Histone-lysine N-methyltransferase EHMT1 2 3 0,02 
Q9Z148-2 Ehmt2 Histone-lysine N-methyltransferase EHMT2 1 1 0,01 
Q8CFE3 Rcor1 REST corepressor 1 3 6 0,08 
Q8BX09-1 Rbbp5 Retinoblastoma-binding protein 5 1 3 0,02 
P55200-1 Kmt2a Histone-lysine N-methyltransferase 2A 1 2 0 
Q9Z2D6-1 Mecp2 Methyl-CpG-binding protein 2 1 1 0,04 
TRANSCRIPTIONAL REGULATORS 
Q61191 Hcfc1 Host cell  factor 1 17 49 0,12 
Q99PV8-1 Bcl11b B-cell  lymphoma/leukemia 11B 12 48 0,2 
Q80YR5 Safb2 Scaffold attachment factor B2 10 25 0,14 
D3YXK2 Safb Scaffold attachment factor B1 11 22 0,14 
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P53564-1 Cux1 Homeobox protein cut-l ike 1 9 20 0,09 
Q00899 Yy1 Transcriptional repressor protein YY1 6 18 0,13 
Q8CH25-1 Sltm SAFB-like transcription modulator 5 13 0,06 
Q03347-1 Runx1 Runt-related transcription factor 1 6 10 0,17 
Q08024-2 Cbfb Core-binding factor subunit beta 3 10 0,18 
Q60974-1 Ncor1 Nuclear receptor corepressor 1 2 4 0,01 
P42225 Stat1 Signal transducer and activator of transcription 1 3 3 0,05 
Q8K0H5 Taf10 Transcription initiation factor TFIID subunit 10 1 2 0,11 
P70353 Nfyc Nuclear transcription factor Y subunit gamma 2 2 0,06 
Q61164 Ctcf Transcriptional repressor CTCF 1 1 0,01 
DNA REPLICATION AND REPAIR 
P11103-1 Parp1 Poly [ADP-ribose] polymerase 1 8 28 0,1 
P54276 Msh6 DNA mismatch repair protein Msh6 7 16 0,06 
Q99J62 Rfc4 Replication factor C subunit 4 3 11 0,08 
Q60596 Xrcc1 DNA repair protein XRCC1 3 8 0,07 
P43247 Msh2 DNA mismatch repair protein Msh2 4 8 0,06 
P35601-1 Rfc1 Replication factor C subunit 1 3 8 0,03 
P97386-1 Lig3 DNA ligase 3 4 7 0,05 
P23475 Xrcc6 X-ray repair cross-complementing protein 6 3 4 0,08 
P17918 Pcna Proliferating cell  nuclear antigen 1 2 0,05 
 
 
 
5. PRC1 alterations in hematopoietic cells deficient in Ring1A, B-gene products 
The relative amounts of PRC1 complexes and their composition could be affected by 
alterations in the concentration of any of their constituent subunits. An example, in ES cells, is 
the negative regulation of CBX products by CBX7, thus becoming the functionally 
predominant PRC1 CBX component in these cells. We have addressed the possibility that 
RING1B or RING1A participate in the stability/composition of PRC1 complexes by quantitative 
analysis of the protein levels of a number of PRC1 subunits in primary hematopoietic cells 
lacking either of these homologs. 
5.1 RING1B-deficient hematopoietic cells 
We took tissues from mice carrying a floxed allele of the Ring1B gene and a Mx-Cre transgene 
whose expression can be induced in the response to poly (I:C). Total cell extracts were 
prepared from bone marrow cells, including populations of Lin-, CD19+ and Ter119+ 
progenitors/precursors and neutrophils, and also from spleen and thymus cell suspensions. 
We analyzed the same set of PRC1 proteins shown in Fig. R1. 
Ac- accession number, UP- unique peptides, SC-spectral counts, COV-coverage 
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Levels of canonical PRC1 subunits in RING1B-deficient cells showed alterations of opposed 
signs, compared to those in control (tissues from mice without MxCre transgene): up 
regulation was seen for RING1A, in all cell types, for PCGF4 in erythroid precursors and for 
CBX2 in primitive progenitors and B-cell precursors (Fig. R25). On the other hand most mutant 
cell types showed decreased levels of PCGF4, PHC2 and CBX subunits. PHC2 levels were 
particularly depressed in Lin- progenitors and in splenocytes (Fig. R25B). The magnitudes of 
these alterations were, in some cases, striking. RING1A levels augmented by 2-3 fold and even 
more, in erythroid progenitors those of PCGF4 or, in B-cells, those of CBX2. However, the 
prevalent consequence of RING1B inactivation was a reduction in levels of canonical PRC1 
subunits, sometimes by up to 1/4 - 1/8 (PCGF4, PHC2) and to a less degree for CBX subunits. It 
would appear that some of these changes would imply functional consequences, for instance 
in Lin- progenitors or spleen cells, which normally expressed the highest PHC2 levels (Fig. R5) 
and where they are more deeply depressed in the absence of RING1B. 
Figure R25. Levels of canonical PRC1 subunits in primary primary hematopoietic cells depleted of RING1B. 
Bars represent differences from values in control cells in two experiments. A log scale was chosen to better 
plot the dual (up regulation, down regulation). 
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Non-canonical PRC1 subunits were less affected, with exceptions. The magnitudes of 
alterations were within the half - double range of values in wild type cells. Among the 
exceptions were neutrophils, where SKP1 and CK2a showed huge opposing changes (Fig. 
R26B, C). An interpretation of these variations, within a PRC1 context, is very difficult because 
these are subunits that also belong into other protein complexes. Opposing changes were 
also observed in the levels of the short form of KDM2B (the full-length variant, as in wild type 
cells, remained in very low levels) in differentiated cells. KDM2B was augmented by 4-fold in 
neutrophils and erythroid precursors and decreased, to the same extent, in spleen cells (Fig. 
R26B).  
 
We have not attempted to investigate the contributions of the possible mechanisms 
(transcriptional, translational/miRNA or of protein homeostasis) that determine protein 
levels. Nevertheless, a major conclusion is that the secondary consequences of gene 
inactivation of RING1B may confound phenotypic analysis. 
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Figure R26. Levels of non-canonical PRC1 subunit in primary hematopoietic cells depleted of RING1B. 
Data plotted as in Fig. R25 
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5.2 RING1A-deficient hematopoietic cells 
Quantiation of PRC1 subunits in hematopoeitic Ring1A-/- cells also showed some differences 
with wild type mice (Figs R27 and 28). However, the magnitud of the alterations was modest 
compared to those seen in RING1B-deficient cells. When the levels increased, the did by a <2 
factor. In a few cases, levels were depressed to less than half of those in controls (YAF2 in  
 
 
 
thymus, KDM2B in thymus cells or PCGF6 in Lin- progenitors). RING1B levels rose in most cell 
types, except in thymus, where they even decreased (Fig. R27A) suggesting a complex 
interrelationship between RING1A and RING1B paralogs. Most surprising was that levels of 
canonical PRC1 subunits were almost unchanged with the exception of CBX7, which was 
increased in CD19+ cells, or CBX2, whose expression was reduced in erythroid precursors. 
Together with data of RING1B-deficient cells, the results showed a larger influence of RING1B 
in sustaining the PRC1 system, even if these alterations are not dramatically reflected in the 
global levels of H2AUb (Fig. R29): while RING1B deficiency impacted the extent of H2AUb 
Figure R27. Levels of canonical PRC1 subunits in primary hematopoietic cells depleted of RING1A. Data 
plotted as in Fig. R25. 
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more clearly than the absence of RING1A (relative values between 0.4 - 0.76 for RING1B-
deficiente cells, compared with 0.75 - 0.99 if RING1A was missing). 
 
 
 
 
 
 
Figure R28. Levels of non-canonical PRC1 subunits in primary primary hematopoietic cells depleted of 
RING1A. Data plotted as in Fig. R25 
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Figure R29. Global H2AUb levels in primary hematopoietic cells depleted of either RING1A or RING1B. 
Data are mean values of the differences between mutant and control cells, after normalization by histone 
H3 content. SD values ranged from 0.1 to 0.17. 
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5.3 Hematopoietic cells double deficient in RING1A and RING1B 
An attempt to generate a hematopoietic compartment lacking both RING1 paralogs was done 
using Ring1A-/- mice that also carry a floxed Ring1B allele and the MxCre transgender. 
Induction of Ring1B inactivation after Cre-mediated recombination, however, leads to an 
aplastic scenario whose bone marrow becomes devoid of hematopoietic cells (Vidal & 
Starowicz, 2017). Then we tried to generate cells depleted of RING1A and RING1B by ectopic 
expression of Nup98-HD10 in Ring1A-/-, Ring1Bfl/fl, Cre Lin- progenitors (Fig. R30A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R30. RING1A- and RING1A, RING1B-depleted progenitor cells. Schematic representation of the 
conditional inactivation of RING1B in Nup98-HD10 immortalized primitive progenitors. (B) Cell accumulation 
in cultures subject to the indicated treatments.(C) Representative western blot analysis of RING1A and 
RING1B levels in cells of the indicated genotypes. The effects of RING1 depletion on H2AUb is also shown. 
Deletion of RING1A and RING1B leads to  loss of H2Ak119ub. (D) MGG staining of cytospin preparations from 
the indicated cultures and treatments. Round, compact, regular nuclei cells correspond to undifferentiated 
blasts. Flattened, with evident cytoplasm and irregular nuclei, characteristic of differentiated myeloid cell 
types. (E) Development of differentiation, assessed by MGG staining, over time after treatment in cultures of 
the indicated genotypes. Tx/4'-OHT, 4'hydroxytamoxifen; EtOH, ethanol (vehicle , used as control treatment). 
Data in B and C, are mean values ± SD of three experiments. 
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Once immortal, cultures were given 4'-OHT, to inactivate Ring1B but the consequence of the 
combined depletion of RING1A and RING1B was senescence and cell death. The evolution of 
parallel cultures, after transient treatment with 4’-OHT or vehicle (EtOH), showed a steep 
decline in the rate of cell accumulation, accompanied by quick differentiation, assessed 
morphologically after MGG staining, in double mutant cultures (Fig. R30D,E). In fact, this 
occurred just the same even if only RING1B is inactivated (Fig. R30E) although the effects 
appear slightly delayed compared with the double mutant cells (Fig. R30B,E). In vivo, RING1A 
(or RING1B) can compensate for the absence of the other paralog (Vidal & Starowicz, 2017) 
but it appears that the requirements imposed by the immortalizing influence of Nup98-HD10 
set a scenario of non-redundancy in which RING1A cannot substitute for RING1B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R31. Compared levels of PRC1 subunits in immortal progenitors expressing/lacking RING1A and 
RING1B. Values are mean ± SD of data normalized to those in bone marrow Lin- cells 
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During these attempts, we found that, even though at very low frequency, sometime few cells 
survived and could be expanded in vitro. One of these cultures was then used to quantitate 
levels of PRC1 subunits and also to investigate whether they associate in complexes in the 
absence of both RING1 proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R32. Representative western blots showing the distribution glycerol gradients of PRC1 subunits from 
RING1A and RING1B-depleted progenitors (right). As a comparison, the distribution of closely related cell 
type containing both RING1 proteins is included (left). PRC1 subunits have been split in canonical (A) and 
non-canonical (B) sets. 
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Figure R32 show levels of PRC1 subunits in Nup98-HD10 immortal progenitors with and 
without RING1A and RING1B, referred to the levels of these subunits in bone marrow Lin- 
cells. The results showed that much of PRC1 canonical components were almost gone when 
the cells lacked RING1 proteins (Fig. R31A). CBX7, PCG4 and PHC2 could be detected only at 
very low levels. CBX2 and CBX8 levels, perhaps due to their presence in other molecular 
assemblies, showed little changes. Non-canonical PRC1 subunits, on the contrary not only 
were little affected but in some cases accumulated at very high levels (Fig. R31B). 
 In particular, a 5-fold excess of RYBP, compared to Lin- cells that contained RING1A and 
RING1B, whether from bone marrow of immortalised after Nup98-HD10 expression. YAF2 
levels instead were hardly changed. Whether the increase in RYBP, or in SKP1 and PCGF5, 
reflects transcriptional changes or perturbed proteostasis was not investigated. Whether 
PRC1 subunits in cells defective in RING1A and RING1B assemble in complexes was examined 
using migration in glycerol gradients. The data, Fig. R32, have to be examined carefully 
because the images display no quantitative information. As indicated above, canonical 
subunits CBX7, PCGF4 and PHC2 were present at very low levels. However, the little of them 
is present as part of assemblies of unknown nature rather than as free proteins. Subunits 
normally found in non-canonical complexes also associate to other proteins, except parts of 
RYBP and YAF2 (Fig R32B). The unavailability of RING1A or RING1B, however, seemed to alter 
the nature of some complexes as indicated by PCGF1, which been present at levels higher 
than in cells with RING1 proteins migrates, in mutant cells, as part of smaller assemblies. 
 
Together, the data suggest that, regardless of their E3 ligase activity, RING1A and RING1B play 
roles stabilizing canonical PRC1 subunits and also as framework subunits within PRC1 
complexes. 
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DISCUSSION 
In this work we expand the current understanding of interactions between PRC1 subunits that 
could contribute to clarify mechanisms pertaining chromatin structure and transcriptional 
control. 
 
We find that steady state levels of PRC1 subunits differ greatly among hematopoietic cell and 
that these variations result from regulatory events uncoupled, at least in part, from 
transcriptional mechanisms. The evidence we present also describes heterogeneity of 
assemblies containing PRC1 subunits. Finally, the associations between subunits known to 
cohabit PRC1 complexes varied with hematopoietic cell types and were found very different 
from that of conventional tissue culture cell lines.  
1. PRC1 assemblies 
Our current appreciation of PRC1 complexes is illustrated by the identities of multi protein 
assemblies isolated from relatively homogeneous populations of immortal cells or "unusual" 
cell types, such as ES cells (Gao et al., 2012; Kloet et al., 2016; Ogawa et al., 2002; Sánchez et 
al., 2007; Vandamme et al., 2011). Based on these findings, in vitro constructions from 
recombinant subunits provides the information that can be trusted best and that allows for 
the mapping of interacting domains and, when three-dimensional data exist, determine 
contact sites, etc. We believe that these results represent a good starting point from where to 
progress in solving the biochemical complexity inherent to PRC1 complexes, but that they 
should not dominate our thinking until a better understanding of the system is achieved. For 
instance, the distribution that we see of PRC1 subunits throughout glycerol gradients 
indicates that while the accepted structures are probably present in most cell types other, 
uncharacterized assemblies do exist. An implication of this observation, for example, is that 
the interpretation of maps with chromatin binding sites for PRC1 subunits becomes difficult. 
This is illustrated with ChIP data for RING1B in ES cells: along regions with a high density of 
bound RING1B there were plenty of other regions with much lower occupancy, and the 
responses to RING1B depletion altered differentially both types of genomic sites (Blackledge 
et al., 2014). Likewise, ChIP experiments on mesodermal cells derived from mesoderm 
precursor cells (MES) showed patterns of PRC1 subunits overlapping only partially which were 
difficult to correlate, beyond a global analysis, with transcriptional activity (Morey et al., 2015) 
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Some of the complexes predicted from glycerol gradients appear to be made out of 
interactions not foreseen from the ongoing paradigm. Among the best examples we have 
seen: large sized complexes, in macrophages, contain PCGF4 but not its direct interaction 
PHC2 (Gray et al., 2016) and conversely, high molecular assemblies that contain PHC2 count 
with minor contribution of PCGF4 in MllAf9-transformed progenitors. It is tempting to invoke 
cell type-specific post-translational modifications that promote/prevent interactions between 
subunits known to contact each other. In the same line, we have no explanation for the 
observation that RING1B locates to very large species in some (quiescent and LPS-stimulated 
spleen cells, macrophages) but not in other (thymocytes, or immortal progenitors). 
Furthermore, while the presence of RYBP or YAF2 in the complexes is, but a few exceptions, 
rather homogeneous that of CBX proteins is amazingly diverse. See CBX7: whereas most of it, 
in macrophages, appears as part of very large complexes, in thymus cells or immortal 
progenitors appears as constituent of far smaller complexes. We are aware of the caveat that 
represents not being able to compare molarities for the distinct subunits. We can only 
achieve an approximation to the proportion of each of the subunits forming part of one or 
another complex and whether the distributions parallels, qualitatively, that of other subunits. 
However, for the indicated cases, the segregation of subunits are so extreme that they would 
appear to support safely the conclusion of cell type-specific assemblies (Klauke et al., 2013; 
Morey et al., 2012). The results then, are probably manifestations of the, for the most part, 
unattended aspect of how PRC1 complexes are build up.  
 
The results also show that while both RING1A and RING1B participate of a variety of 
complexes, and that despite their close structural relatedness these are probably separate 
entities. It is not only the differences in migration, but also that when pulling down 
biotinylated-RING1B the amount of RING1A present is just a minor part of all RING1A present. 
Previous evidence, by us (Sánchez et al., 2007) and other groups (Gao et al., 2012; Vandamme 
et al., 2011) reported the concurrent presence of RING1A and RING1B in the same 
complex(es). It is quite possible that a lack of quantitative approach may have contributed to 
a conclusion of cohabitation. Alternatively, the discrepancy may be cell type-related. 
However, at least in hematopoietic cells, the observation poses the assemblies would look 
like, particularly because of (limited) evidence we report supporting question of how RING1A 
115 
 
lack of redundancy between the two paralogs (van den Boom et al., 2013). For example, the 
inability of RING1A to prevent massive differentiation and promote survival of immortal, 
primitive progenitors that express Nup98-HD10. Obviously, the uncertainty of the existence of 
uncharacterized, different from known PRC1 complexes leaves too many unknown variables 
when proposing non-overlapping activities for RING1A or RING1B-containing complexes. 
 
A very similar situation is that of RYBP and YAF2 paralogs, the subunits that are found in all 
non-canonical types of PRC1 complexes. Their levels are clearly regulated in distinct fashion 
and the complexes in which these subunits are found differ too, so that very high molecular 
weight forms containing only YAF2. 
 
2. PRC1 levels 
The large differences in PRC1 protein levels among hematopoietic cell types beg the question 
of how they might impact PRC1 function. Beyond the general observation that, in primary 
cells, levels of PRC1 subunits decreased to a different extent compared to those in primitive 
progenitors contained in the Lin- population, no clear pattern could be established. The 
exception, for canonical subunits, was the population of B-cell precursors (CD19+ cells). In 
particular, it was unexpected to determine the magnitude of the fall in RING1A and RING1B 
levels with differentiation. The lowest levels of canonical subunits in neutrophils may not 
need of an interpretation considering their short lifespan but only if PRC1 function is 
considered under the usual perspective of "memory maintenance". Indeed, most functions in 
differentiated cell types, unveiled through loss-of-function mutations, are associated to 
longer lived, lymphoid cells (Beguelin et al., 2016; Ikawa et al., 2016). A switch of CBX 
subunits, from CBX7 to CBX8 has been shown in primitive hematopoietic progenitors (Klauke 
et al., 2013) so that CBX7 expression in the most undifferentiated type is silenced to turn on 
that of its paralog CBX8. The process parallels that previously shown in ES cells and its 
differentiated descendents (Morey et al., 2012). Also, during the progress of this thesis, a 
systematic comparison between the contents of PcG proteins in ES cells and neural 
progenitors shows that the differences were reflected in the nature of the complexes formed 
(Kloet et al., 2016). Here, is worth insisting in that the differences in content reported refer 
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only to individual subunits and that quantitatively are independent of each other, due to 
limitations in the methodology used.  
Looking at the expression of mRNAs encoding these subunits (Fig. D1) it is plainly evident the 
lack of correlation with protein levels. The comparison shown in Fig. D1 includes only primary 
cells since we have no data for immortalized progenitors (de Graaf et al., 2016). As it has been 
mentioned above, protein levels, whether of canonical or non-canonical PRC1 subunits are 
lower in every cell type tested when compared with those in primitive, Lin- progenitors. And 
yet, mRNA levels in the two groups of progenitors that make that pool are not consistently 
higher than those measured in more differentiated cell types which, in contrast contain much 
reduced levels of protein. Taking more differentiated cell types the conclusion is similar even 
though in some cases the correlation between mRNA and protein levels may hold, at least in 
part.  
Whichever regulatory pathway is involved we think it is affected by the proliferative status of 
the cell. Our comparison of spleen cells between the quiescent population and that of cells 
taken into proliferation by LPS, however, is affected by the very different conditions the cells 
are: in the first case they were simply taken from the mouse whereas, in the second, the cells 
had grown in enriched media under non-physiological dosages of oxygen. The latter 
conditions are bound to altermetabolic/energetic rates. However, the comparison of 
immortal progenitors growing in the same rich medium but differing extremely in their 
proliferative rates also sustains the conclusion that, on average, dividing cells tend to be 
equipped with higher levels of PRC1 subunits. Of note, among the primary cells studied, even 
if not actively dividing, the Lin- population enriched in PRC1 subunits contains the larger 
proportion of cells undergoing proliferation.  
Lastly, it was surprising the realization of how the content of PRC1 subunits was altered by the 
depletion of RING1B, and how the deficiency in RING1A, instead, turned out to produce very 
mild effects. Thus, although the levels of most subunits in RING1B-deficient cells 
decreased/increased by half/double compared to control cells, in some cases variations were 
far more extreme with opposing alterations depending on the cell type. 
The minor effects seen in RING1A-deficient cells could be argued that is the consequence of 
adaptations associated to the nature of the mutation: tissues depleted of RING1A throughout 
development where some adjustment may have taken place to ameliorate negative effects of 
the mutation. 
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Compared to such a constitutive depletion, our conditional deletion of RING1B may appear 
more as an acute inactivation. However, our in vivo depletion of RING1B differs from an 
abrupt inactivation as that seen after 4'-OHT-induced depletion in cultured cells. The reason is 
that in our protocol, we waited for a substantial period, 8-10 weeks, of time pass after 
RING1B depletion, in order to ensure complete loss of RING1B in the longer-lived lymphoid 
compartment. Not having examined mRNA levels encoding PRC1 subunits in mutant cells we 
cannot elaborate on the nature of the mechanism involved. It is worth noting, however, that 
Figure D1. mRNA expression of chosen Polycomb products in hematopoietic cells.(A) RING proteins and 
canonical subunits. (B) non-canonical subunits. MPP- multipotent progenitor, RPP - restricted potential 
progenitor 
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whereas RING1A protein levels are unregulated in all cell types studied, other subunits 
showed changes towards accumulation or reduction. Therefore, a lineal relationship with 
transcriptional activity is difficult, more so  considering the residence, in differentiated cells, 
of PRC1 complexes on both, silent and active loci (Frangini et al., 2013; Kloet et al., 2016; 
Loubiere et al., 2016; Morey et al., 2015; Schaaf et al., 2013). 
3. PRC1 complexes as seen in pull-down experiments 
In this work we have attempted to identify, among known PRC1 components, possible cell 
type-selective interactions. PRC1 complexes, with few exceptions, have been identified in 
isolation procedures that involve affinity steps with one, and often two tags present in one of 
the members of the complex(es). Following protocols devised long time ago for the extraction 
of transcription factors, perhaps an epitome of nuclear proteins, antibodies or, as in our case, 
streptavidin bind the tagged protein and pull down with it the associated subunits. Our 
choosing of streptavidin was based in the very high affinity for biotin, which allowed for 
efficient binding of most biotinylated protein. Coupled with a parallel process in which an 
equivalent extracts but with no tagged protein is used for an estimation of material retained 
non-specifically during the experiment, it appears, on paper, as an ideal approach. Indeed, 65-
95% of RING1B present in extracts (of all, in fact, considering that cells expressed only tagged 
RING1B) was isolated from the nuclear extracts. Such an efficient purification would facilitate 
the (quantitative) study of the association of chosen PRC1 subunits. Here a clarification is due 
and is that our pull down analysis cannot discriminate among biochemical entities since we 
consider everything eluted from the beads. The identification mentioned above makes use of 
biochemical fractionation techniques, such as column chromatography (see Ogawa et al., 
2002) 
 
As it could be expected, if PRC1 subunits are part of RING1B-free complexes, a more modest 
fractions of the total amount of these subunits present in each cell was found bound to 
RING1B. The option that a population of molecules is not in protein complexes can be ruled 
out from the glycerol gradient data. Given that hardly any RING1A is part of RING1B-
complexes, a major source of these assemblies, would be "parallel" PRC1 complexes 
nucleated around RING1A. This, however, is a prediction remaining to be tested and, 
certainly, the differences in distribution of RING1A- and RING1B-containing complexes 
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evidenced in glycerol gradients suggest that PRC1 containing assemblies containing one or 
another RING1 parlog will be similar only in part. Additional signs of such a dissimilar 
architectures are the skewed presence of direct interactors in RING1B complexes. Depending 
on cell type, CBX7 or PCGF1 are subunits pulled down with very high efficiency, as if 
associated preferentially with RING1B and, therefore, unavailable to be part of RING1A-
complexes. This is surely one of the leads to follow, the characterization of PRC1 complexes 
containing RING1A. This would help clarifying whether the poor presence of RYBP/YAF2 or of 
CBX2 on RING1B-complexes is a consequence of a preferential engagement with RING1A or, 
simply that they belong into alternative assemblies. The presence of CBX8 in non PRC1 
complexes (Chung et al., 2016) is an example. 
 
An interesting observation in our pull down experiments is the unexpected instability of the 
associations between PRC1 subunits. As a measure of this, we estimated the proportion of 
protein initially bound to beads and subsequently lost following washes required to remove 
non-specifically bound proteins. In other words, they are associated as if they were part of 
the background binding. Being known RING1B interactors (whether direct or indirect) such an 
interpretation is ruled out and, instead, we favor the possibility that contacts within the 
RING1B-complexes are labile. This implies a methodological problem that we will deal with 
below, but the extent to which binding was more or less robust showed a dependency on the 
subunit and also with the cell type. In particular, it could not be anticipated that, for instance, 
so few of the PRC1 subunits and so little of them remained bound to RING1B in pull down 
experiments with extracts from immortalized Nup98-HD10 progenitors. Note that during the 
optimization steps, washing conditions were mild, without increased ionic strength! Less 
extreme situations, however, involved both indirect and also direct RING1B interactions. In 
LPS-stimulated spleen cells, for instance, it is more CBX7 and CBX8 that are washed away than 
that remains bound to beads. If a tendency is to be shown, perhaps the subunits thought to 
form non-canonical complexes interact in a more labile fashion. Moreover, not even the 
assumption that unstable associations, usually considered to take place among non-core 
subunits of complexes, are restricted to proteins that bind indirectly RING1B. It is the case of 
RYBP, which does not withstand washes and a large fraction of it initially bound to the beads 
is lost with washes. Perhaps the abundant presence of PRC1 subunits in fractions of the 
glycerol gradients corresponding to the migration of proteins of ≤150 kDa is an indication of 
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dynamic association-dissociation which, at concentrations much lower of those within the 
nucleus results in being washed away when removing background binding. The question that 
arises is whether this dynamic behavior is regulated, as part of a controlled activity of PRC1 
(and other) assemblies. Certainly, the "strength" of binding differed among subunits and also 
varied with cell types. It is not rare that binding of >60% of the protein present in the extract 
was reduced to a much smaller fraction after washes, eventually. Obviously, even if this 
determined physiologically it poses a serious concern when attempting quantitative analysis, 
say using mass-spectroscopy, because much of the bona fide bound protein in vivo is being 
lost during pull down experiments. Perhaps this would demand a clever usage of cross-linking 
agents which would complicate analysis in extreme. Currently, such a cross-linking step is 
usually carried out on protein bound to beads, i.e. after washes, with the intention of 
detecting contacts protein-protein (Kloet et al., 2016). That would not be a solution because 
labile associations would be lost prior to cross-linking. That we have not come across a trivial 
artifact (other labs would have identified already!) is clear from the fact that our analysis with 
one of the cell types most commonly used, 293 cells, resulted in the expected scenario of 
robust binding. Extending pull down experiments to other, physiological/primary cell types, 
should assist in determining the actual behavior of PRC1 complexes in vivo. Together with the 
observations that just the depletion of a given subunit may lead to secondary effects, the 
results call for a more patient approach using allelic series as the effective way to study 
function of PRC1 and that of other complexes that regulate chromatin. 
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CONCLUSIONS 
 
1. Although known PRC1 subunits assemblies were identified in hematopoietic cells, increased 
complexity was also found, suggesting that accepted notions are but a simplification of 
physiological settings much harder to accommodate to idealized models. 
 
2. Overall levels of canonical and non-canonical subunits decrease with differentiation of 
primary hematopoietic cells, in ways apparently uncoupled from transcriptional control. Only 
ex-vivo expanded and immortal cell types contain levels equal or higher than those of 
immature progenitors. 
 
3. A large proportion of each PRC1 subunit forms assemblies of size and complexities that 
vary with cell type. Their identities do not match that of described complexes. Thus, cells of 
different lineages seem endowed with distinct, only partially overlapping sets of PRC1 
assemblies.  
 
4. Core PRC1 subunits RING1A and RING1B, as well as paralogs RYBP and YAF2, common to all 
non-canonical complexes, associate in very different types of assemblies, with only RING1B 
and YAF2 present among the largest assemblies. 
 
5. Some of the (uncharacterized) complexes detected do not conform to interactions 
expected from known PRC1 assemblies. 
 
6. Associations between PRC1 subunits in hematopoietic cells are far more unstable than 
those in tissue culture cells that lay the foundations of our current understanding of PRC1 
assemblies. 
 
7. Association lability affects direct interactors in cell types such as immortal progenitors 
instability is extreme. Besides possible biological implications, the observation poses a serious 
challenge to quantitative characterization of PRC1 complexes. 
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8. Steady-state levels of PRC1 subunits are altered, severely in some cases, in the absence of 
RING1B, but not of RING1A. This implies that a targeted genetic analysis, i.e. allelic series, may 
be required to solve uncertainties of the common, global loss-of-function analysis. 
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CONCLUSIONES 
 
1. Aunque las subunidades conocidas de PRC1 y sus interacciones se han identificado en 
células hematopoyéticas, nuestros resultados también muestran una complejidad de 
elementos PRC1 que precisa de modificaciones del modelo idealizado del paradigma actual. 
 
2. Los niveles de subunidades PRC1, en complejos canónicos y no canónicos, disminuyen con 
la diferenciación hematopoyética. Estos niveles parecen desacoplados, al menos en parte, del 
control transcripcional. Sólo los cultivos de células expandidas ex-vivo contienen niveles de 
subunidades PRC1 que igualan  o son superiores a los de progenitores. 
 
3. Una parte considerable de cada subunidad PRC1 forma parte de complejos de tamaño y 
heterogeneidades que varían con el tipo celular; algunos de dichos complejos difieren 
claramente de los conocidos. Parecería, entonces, que cada tipo celular está dotado de un 
conjunto de complejos PRC1 compartido sólo parcialmente con otros tipos celulares. 
 
4. Algunos de los complejos que contienen RING1B no contienen RING1A y, análogamente, 
los que contienen YAF2 no contienen RYBP, de modo que sólo RING1B y YAF2 forman parte 
de complejos de alto peso molecular. 
 
5. Algunos de los complejos observados no responden a las interacciones esperables de 
complejo conocidos PRC1. 
 
6. En células hematopoyéticas, las asociaciones entre subunidades PRC1 son mucho más 
inestables que las descritas en las líneas celulares utilizadas en estudios previos. 
 
7. La inestabilidad de las asociaciones afecta incluso a proteínas que interaccionan 
directamente. Además de posibles implicaciones biológicas, la observación deberá ser tenida 
en cuenta para la caracterización cuantitativa de complejos PRC1. 
 
8. Los niveles estacionarios de las subunidades se alteran, severamente en algunos casos, en 
ausencia de RING1B pero no de RING1A. En consecuencia, un análisis genético dirigido, por 
126 
 
ejemplo, de series alélicas, puede ser necesario para resolver incertidumbres del análisis 
común de pérdida de función global. 
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